Lothar Prof Dr Kanz

Lothar Prof Dr Kanz's AcademicInfluence.com Rankings

Lothar Prof Dr Kanz

Philosophy

#5476

World Rank

#8290

Historical Rank

Logic

#2748

World Rank

#3782

Historical Rank

philosophy Degrees

Lothar Prof Dr Kanz

Biology

#7338

World Rank

#10241

Historical Rank

Immunology

#393

World Rank

#408

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Lothar Prof Dr Kanz's Degrees

PhD Physics University of Hamburg
Masters Physics University of Hamburg

Why Is Lothar Prof Dr Kanz Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Lothar Prof Dr Kanz's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. (2002) (733)
Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids (2000) (675)
The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. (1998) (669)
Detection and identification of fungal pathogens in blood by using molecular probes (1997) (603)
Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. (2000) (557)
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. (2003) (532)
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial (2012) (507)
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. (2010) (476)
Novel Markers for the Prospective Isolation of Human MSC (2007) (458)
Treatment of older patients with mantle-cell lymphoma. (2012) (453)
Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors [see comments] (1994) (410)
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) (2012) (401)
Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. (2002) (398)
Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. (1995) (381)
Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1 (2009) (358)
Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. (1999) (339)
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). (2006) (330)
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. (2016) (325)
Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. (2008) (311)
Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47. (1999) (298)
Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation (1997) (291)
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network (2016) (289)
Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. (2011) (282)
Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. (2003) (281)
Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. (1996) (269)
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. (2014) (269)
Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin (1993) (265)
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. (2011) (262)
Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. (1998) (253)
Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. (1998) (249)
Heterogeneity among human bone marrow-derived mesenchymal stem cells and neural progenitor cells. (2003) (248)
Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. (2016) (248)
Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. (2010) (247)
Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. (1994) (243)
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. (2006) (238)
Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection (2000) (237)
Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. (1992) (216)
The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. (2001) (215)
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV (2015) (213)
Enhanced Erythrocyte Apoptosis in Sickle Cell Anemia, Thalassemia and Glucose-6-Phosphate Dehydrogenase Deficiency (2002) (208)
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. (2010) (208)
Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT (1998) (204)
Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma (2011) (203)
Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. (2000) (199)
Platinum organ toxicity and possible prevention in patients with testicular cancer (1999) (199)
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. (2011) (197)
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion (2019) (195)
Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells. (2001) (190)
The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors. (1999) (190)
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants (2017) (189)
Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1) (1999) (188)
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. (2010) (187)
Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. (2004) (181)
NOA‐03 trial of high‐dose methotrexate in primary central nervous system lymphoma: Final report (2005) (179)
Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. (1998) (177)
Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer. (1998) (173)
Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. (2002) (169)
Topotecan – A Novel Topoisomerase I Inhibitor: Pharmacology and Clinical Experience (1999) (166)
Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. (2000) (162)
German Cancer Society Neuro‐Oncology Working Group NOA‐03 multicenter trial of single‐agent high‐dose methotrexate for primary central nervous system lymphoma (2002) (159)
Functional response of leukaemic blasts to stromal cell‐derived factor‐1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia (2000) (159)
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. (1999) (153)
Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. (2001) (151)
The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34+ progenitor cells. (2004) (149)
Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. (2007) (148)
Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. (2008) (146)
HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL) (2014) (146)
Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin (1994) (146)
Phenotypic Characterization of Distinct Human Bone Marrow–Derived MSC Subsets (2009) (144)
Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. (2001) (140)
The basophil activation marker defined by antibody 97A6 is identical to the ectonucleotide pyrophosphatase/phosphodiesterase 3. (2001) (139)
SOX2 expression associates with stem cell state in human ovarian carcinoma. (2013) (138)
Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. (2003) (136)
Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. (2000) (136)
Dendritic cells in cancer vaccines. (2001) (135)
Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. (2004) (134)
Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. (1999) (134)
Primary malignant sarcomas of the heart and great vessels in adult patients--a single-center experience. (2007) (133)
Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia. (2000) (130)
Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. (1997) (130)
Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. (1999) (126)
Chemotaxis and transendothelial migration of CD34(+) hematopoietic progenitor cells induced by the inflammatory mediator leukotriene D4 are mediated by the 7-transmembrane receptor CysLT1. (2001) (124)
Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. (2010) (123)
Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation. (1998) (123)
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib (2014) (123)
Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor. (1998) (122)
Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. (2003) (120)
Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. (1999) (119)
Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study (2012) (118)
Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. (2004) (116)
A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer (2000) (115)
Cross‐linking of the T cell receptor complex with the subset‐specific differentiation antigen stimulates interleukin 2 receptor expression in human CD4 and CD8 T cells (1987) (113)
Treatment of brain metastases in patients with testicular cancer. (1997) (111)
Hematopoietic Development from Human Induced Pluripotent Stem Cells (2009) (111)
Follow‐up of patients with progressive multiple myeloma undergoing allografts after reduced‐intensity conditioning (2003) (111)
The Role of Sphingosine 1‐Phosphate Receptors in the Trafficking of Hematopoietic Progenitor Cells (2005) (110)
Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin. (1993) (110)
Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials (2004) (109)
Inhibitory effect of imatinib on normal progenitor cells in vitro. (2004) (106)
Detection of cytomegalovirus DNA in CD34+ cells from blood and bone marrow. (1995) (106)
Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. (2011) (105)
Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. (2002) (104)
Expression and secretion of vascular endothelial growth factor-A by cytokine-stimulated hematopoietic progenitor cells. Possible role in the hematopoietic microenvironment. (2000) (104)
Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. (2002) (100)
Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies (1998) (98)
Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma. (1999) (98)
The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. (2015) (97)
Phenotypic and functional heterogeneity of human bone marrow– and amnion‐derived MSC subsets (2012) (95)
Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. (2001) (95)
Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. (2007) (94)
Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy (2014) (94)
Maintenance of transplantation potential in ex vivo expanded CD34(+)- selected human peripheral blood progenitor cells (1994) (94)
A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). (2006) (93)
Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma (2002) (91)
Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity. (2006) (91)
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib (2014) (89)
Ex vivo generation of human cytomegalovirus‐specific cytotoxic T cells by peptide‐pulsed dendritic cells (2001) (89)
Generation of Functional Human Dendritic Cells From Adherent Peripheral Blood Monocytes by CD40 Ligation in the Absence of Granulocyte-Macrophage Colony-Stimulating Factor (1998) (88)
Therapy‐related malignancies following treatment of germ cell cancer (1999) (88)
Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signaling. (2013) (86)
[18F] FDG-PET/CT as a new and sensitive imaging method for the diagnosis of large vessel vasculitis. (2008) (86)
Maintenance of transplantation potential in ex vivo expanded CD34(+)-selected human peripheral blood progenitor cells. (1994) (85)
Cyclophosphamide for large vessel vasculitis: assessment of response by PET/CT. (2011) (85)
AC133 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursors. (1999) (83)
A Randomized Trial Comparing the Nephrotoxicity of Cisplatin/Ifosfamide-Based Combination Chemotherapy with or without Amifostine in Patients with Solid Tumors (2000) (81)
Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: results of a phase I study. (1992) (80)
Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. (2001) (79)
Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition. (2008) (78)
Induction of Adipophilin-Specific Cytotoxic T Lymphocytes Using a Novel HLA-A2-Binding Peptide That Mediates Tumor Cell Lysis (2004) (78)
Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. (2003) (76)
Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte‐colony stimulating factor accelerate both neutrophil and platelet recovery after high‐dose VP16, ifosfamide and cisplatin (1993) (75)
In vitro Myogenic Differentiation of Human Bone Marrow–Derived Mesenchymal Stem Cells as a Potential Treatment for Urethral Sphincter Muscle Repair (2009) (74)
Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [18F]FDG PET (2002) (74)
Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin. (1992) (74)
Regulation of Transendothelial Migration of Hematopoietic Progenitor Cells (1999) (74)
Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. (2007) (74)
Successful treatment of human herpesvirus-6 encephalitis after bone marrow transplantation (1999) (72)
A phase I/II study of sequential, dose‐escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas (1997) (71)
Late toxicity following curative treatment of testicular cancer. (1999) (70)
The benefit of using whole‐body, low‐dose, nonenhanced, multidetector computed tomography for follow‐up and therapy response monitoring in patients with multiple myeloma (2007) (70)
Immune reconstitution after haploidentical hematopoietic cell transplantation: impact of reduced intensity conditioning and CD3/CD19 depleted grafts (2011) (66)
Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling. (2000) (65)
High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a cross-sectional study (2014) (64)
Hematopoietic growth factors for hematopoietic stem cell mobilization and expansion. (2007) (63)
T cells and probably B cells arise from the malignant clone in chronic myelogenous leukemia. (1985) (62)
Expression of Novel Surface Antigens on Early Hematopoietic Cells a (1999) (61)
CDCP1 Is a Novel Marker for Hematopoietic Stem Cells (2003) (61)
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML (2015) (61)
Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy (2015) (60)
Optimization of Autologous Stem Cell Transplantation for Systemic Sclerosis — A Single-center Longterm Experience in 26 Patients with Severe Organ Manifestations (2012) (60)
Mixed response to tocilizumab for ankylosing spondylitis (2010) (60)
Rituximab for treatment-resistant extensive Wegener`s granulomatosis—additive effects of a maintenance treatment with leflunomide (2007) (59)
Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation (2017) (59)
Analysis of Risk Factors for Cisplatin-Induced Ototoxicity in Patients With Testicular Cancer (1998) (59)
First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases. (2000) (59)
Magnetic resonance imaging guided corticosteroid injection of the sacroiliac joints in patients with therapy resistant spondyloarthropathy: a pilot study. (2000) (59)
An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma (2006) (58)
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV (2013) (57)
Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): results of a pilot study (1999) (57)
BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. (2006) (57)
HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin’s lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG) (2005) (56)
Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis. (2013) (55)
Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody Trastuzumab. (1999) (54)
Paradigm Shift in the Management of Irresectable Colorectal Liver Metastases: Living Donor Auxiliary Partial Orthotopic Liver Transplantation in Combination With Two-stage Hepatectomy (LD-RAPID). (2019) (53)
Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors. (1996) (53)
The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group. (1998) (52)
Expansion of cord blood CD34+ hematopoietic progenitor cells in coculture with autologous umbilical vein endothelial cells (HUVEC) is superior to cytokine-supplemented liquid culture (2005) (52)
Clinical Applications of CD34+ Peripheral Blood Progenitor Cells (PBPC) (2000) (52)
The German National Registry of Primary Immunodeficiencies (2012–2017) (2019) (52)
Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. (2011) (51)
Symptomatic bone marrow involvement in breast cancer--clinical presentation, treatment, and prognosis: a single institution review of 22 cases. (2011) (51)
Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer (2002) (51)
CLONAL SELECTION OF CD20‐NEGATIVE NON‐HODGKIN'S LYMPHOMA CELLS AFTER TREATMENT WITH ANTI‐CD20 ANTIBODY RITUXIMAB (1999) (51)
First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial (2003) (50)
The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. (2018) (49)
Signal-regulatory protein a ( SIRP a ) but not SIRP b is involved in T-cell activation , binds to CD 47 with high affinity , and is expressed on immature CD 34 1 CD 38 2 hematopoietic cells (2001) (49)
Mucormycoses in patients with hematologic malignancies: an emerging fungal infection. (2005) (49)
CMV iNFECTION AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION IS ASSOCIATED WITH THE OCCURRENCE OF VARIOUS AUTOANTIBODIES AND MONOCLONAL GAMMOPATHIES (1996) (48)
Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation. (1997) (48)
Transendothelial Migration of Hematopoietic Progenitor Cells (2001) (47)
A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma (2003) (47)
Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation. (2018) (47)
Hyperchloremic metabolic acidosis with high serum potassium in renal transplant recipients: a cyclosporine A associated side effect. (1986) (46)
A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. (1997) (46)
Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation (2005) (46)
Unicellular-unilineage erythropoietic cultures: molecular analysis of regulatory gene expression at sibling cell level. (1999) (45)
Generation of antigen‐presenting cells for soluble protein antigens ex vivo from peripheral blood CD34+ hematopoietic progenitor cells in cancer patients (1996) (45)
Aberrant expression of the homeobox gene CDX2 in pediatric acute lymphoblastic leukemia. (2009) (45)
In vivo effects of interleukin-6 on thrombopoiesis in healthy and irradiated primates [see comments] (1992) (45)
Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer (2005) (44)
EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia (2013) (44)
Dendritic cells in vaccination therapies of human malignant disease. (2004) (44)
Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes (2016) (44)
Ex vivo expansion of CD34+ peripheral blood progenitor cells: implications for the expansion of contaminating epithelial tumor cells. (1996) (43)
Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. (1994) (43)
Paclitaxel-induced radiation recall dermatitis. (1996) (43)
In vivo effects of interleukin-6 on thrombopoiesis in healthy and irradiated primates. (1992) (43)
Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera (2006) (43)
SOX2 Expression and Prognostic Significance in Ovarian Carcinoma (2013) (42)
Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO. (2005) (42)
A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplanation (2001) (42)
Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo (2002) (41)
Myeloablative and Reduced-intensity conditioned Allogeneic Haematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of EBMT. (2019) (40)
Modulation of CXC Chemokine Receptor Expression and Function in Human Neutrophils during Aging In Vitro Suggests a Role in Their Clearance from Circulation (2009) (40)
Autologous stem cell transplantation of treatment-resistant systemic vasculitis--a single center experience and review of the literature. (2005) (39)
Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury (2012) (39)
Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer (2002) (39)
Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. (1999) (39)
Thyroid toxicity of treatment for Hodgkin's disease (2000) (39)
Extragonadal germ cell tumors: relation to testicular neoplasia and management options (2003) (39)
Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma (2007) (39)
The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors (2000) (39)
Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. (2019) (39)
Immune regulatory loops determine productive interactions within human T lymphocyte-dendritic cell clusters. (1999) (39)
Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters. (2008) (38)
Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality. (2001) (38)
KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts (2014) (38)
Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party (2020) (38)
Absence of c‐KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer (2002) (38)
Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma (2009) (37)
Ex vivo expansion of hematopoietic progenitor cells for clinical use. (1998) (37)
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer. (1997) (37)
Bendamustine hydrochloride in patients with refractory soft tissue sarcoma (2007) (37)
The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors (2000) (36)
Expression of stage-specific embryonic antigen-4 (SSEA-4) defines spontaneous loss of epithelial phenotype in human solid tumor cells. (2015) (36)
Type 2 diabetes mellitus and risk of malignancy: is there a strategy to identify a subphenotype of patients with increased susceptibility to endogenous and exogenous hyperinsulinism? (2010) (36)
German consensus on immunogenetic donor search for transplantation of allogeneic bone marrow and peripheral blood stem cells (1997) (36)
Accelerated telomere shortening in glycosylphosphatidylinositol (GPI)-negative compared with GPI-positive granulocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) detected by proaerolysin flow-FISH. (2005) (36)
Evaluation of Murex CMV DNA Hybrid Capture Assay for Detection and Quantitation of Cytomegalovirus Infection in Patients following Allogeneic Stem Cell Transplantation (1998) (35)
HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy (2017) (35)
Primary central nervous system (CNS) lymphoma in immunocompetent patients (2002) (35)
Expression of her-2/neu on acute lymphoblastic leukemias: implications for the development of immunotherapeutic approaches. (2003) (35)
Antibody W7C5 Defines a CD109 Epitope Expressed on CD34+ and CD34− Hematopoietic and Mesenchymal Stem Cell Subsets (2003) (34)
PET/CT with 18F-FLT: Does It Improve the Therapeutic Management of Metastatic Germ Cell Tumors? (2010) (34)
Avascular necrosis of bone following allogeneic stem cell transplantation: MR screening and therapeutic options (1997) (34)
Molecular and functional interactions between AKT and SOX2 in breast carcinoma (2015) (34)
Prominent Oncogenic Roles of EVI1 in Breast Carcinoma. (2017) (34)
Treatment of patients with cisplatin‐refractory testicular germ‐cell cancer (1999) (34)
Evi1 regulates Notch activation to induce zebrafish hematopoietic stem cell emergence (2016) (34)
Primary central nervous system lymphoma 1991–1997 (2001) (34)
Randomized Comparison of Interferon-a With Busulfan and Hydroxyurea in Chronic Myelogenous Leukemia (2002) (34)
Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide. (2000) (34)
Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations. (2014) (34)
Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. (2003) (33)
Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer. (1997) (33)
Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV. (2009) (32)
Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy (2015) (32)
NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia (2017) (32)
R-CHOP Versus R-FC Followed by Maintenance with Rituximab Versus Interferon-Alfa: Outcome of the First Randomized Trial for Elderly Patients with Mantle Cell Lymphoma (2011) (31)
Developmental regulation of myeloid gene expression and demethylation during ex vivo culture of peripheral blood progenitor cells. (1996) (30)
Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation (2019) (30)
Allogeneic Stem Cell Transplant Versus Tandem High-Dose Melphalan for Front-Line Treatment of Deletion 13q14 Myeloma – An Interim Analysis of the German DSMM V Trial. (2009) (29)
Transmission of psoriatic arthritis by allogeneic bone marrow transplantation for chronic myelogenous leukaemia from an HLA-identical donor. (1999) (29)
Normalization of Previously Shortened Telomere Length under Treatment with Imatinib Argues against a Preexisting Telomere Length Deficit in Normal Hematopoietic Stem Cells from Patients with Chronic Myeloid Leukemia (2003) (29)
HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy (2016) (29)
Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO‐incompatible red blood cell transfusion (2015) (29)
Complete remission of relapsing high-grade angiosarcoma with single-agent metronomic trofosfamide (2006) (28)
Human Recombinant Interferon-α2a (rhIFNα2a) for the Treatment of Behçet’s Disease with Sight-Threatening Retinal Vasculitis (2004) (28)
Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia (2013) (28)
Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial (2017) (28)
HHV8 associated Kaposi's sarcoma during triple immunosuppressive treatment with cyclosporin A, azathioprine, and prednisolone for ocular Behçet's disease and complete remission of both disorders with interferon α (2001) (28)
Approaches to Dendritic Cell‐Based Immunotherapy after Peripheral Blood Stem Cell Transplantation (1999) (28)
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV (2018) (27)
Transendothelial migration of hematopoietic progenitor cells. Role of chemotactic factors. (2001) (27)
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis (2019) (26)
Successful transplantation of highly selected CD34+ peripheral blood stem cells in a HLA-sensitized patient treated with immunoadsorption onto protein A. (2000) (26)
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis (2019) (26)
Extramedullary relapses at uncommon sites after allogeneic stem cell transplantation (2000) (26)
Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma (2011) (26)
How many myeloid post-progenitor cells have to be transplanted to completely abrogate neutropenia after peripheral blood progenitor cell transplantation? Results of a computer simulation. (1999) (26)
Fludarabine may induce durable remission in patients with leptomeningeal involvement of chronic lymphocytic leukemia (2005) (26)
Clonal Heterogeneity in Growth Kinetics of CD34+CD38− Human Cord Blood Cells In Vitro Is Correlated with Gene Expression Pattern and Telomere Length (2005) (25)
Sequential chemotherapy followed by reduced‐intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT (2017) (25)
Positron emission tomography helps to diagnose tumor emboli and residual disease in choriocarcinoma. (1996) (25)
Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation (2020) (25)
Blood cell transplantation: report from an International Consensus Meeting. (1994) (25)
Ex vivo manipulation of hematopoietic stem and progenitor cells. (1998) (24)
Combined Modality Treatment of Two or Four Cycles of ABVD Followed by Involved Field Radiotherapy in the Treatment of Patients with Early Stage Hodgkin’s Lymphoma: Update Interim Analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG). (2005) (24)
Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia—a randomized, placebo-controlled, double-blind safety and efficacy study (2003) (24)
Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer. (1999) (24)
Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer. (1995) (24)
A new case of Carney triad: gastrointestinal stromal tumours and leiomyoma of the oesophagus do not show activating mutations of KIT and platelet-derived growth factor receptor α (2006) (24)
Detection of Epstein-Barr Virus DNA in Plasma from Patients with Lymphoproliferative Disease after Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation (1999) (23)
The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia. (2014) (23)
Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation (2015) (23)
Additional transplantation of ex vivo generated megakaryocytic cells after high-dose chemotherapy. (2004) (23)
An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma (2003) (23)
Clinical impact of germ cell tumor cells in apheresis products of patients receiving high-dose chemotherapy. (2001) (22)
Severe paraneoplastic hypereosinophilia in metastatic renal cell carcinoma (2012) (22)
Management of disseminated intravascular coagulopathy with direct factor Xa inhibitor rivaroxaban in Klippel-Trénaunay syndrome. (2013) (22)
AEROBIC EXERCISE IN THE REHABILITATION OF CANCER PATIENTS 1578 (1997) (22)
Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma (2012) (22)
Is Continuous 24-Hour Infusion of 5-Fluorouracil plus High-Dose Folinic Acid Effective in Patients with Progressive or Recurrent Colorectal Cancer? (1998) (22)
Role of Consolidation Therapy in the Treatment of Patients up to 60 Years with High Risk AML. (2005) (22)
Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia. (2003) (22)
Induction of Minor Histocompatibility Antigen HA-1–Specific Cytotoxic T Cells for the Treatment of Leukemia After Allogeneic Stem Cell Transplantation (1999) (22)
Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia (2018) (22)
Role of Postchemotherapy Surgery in the Management of Patients With Liver Metastases From Germ Cell Tumors (2005) (22)
Long-term follow-up on a patient with incomplete POEMS syndrome undergoing high-dose therapy and autologous blood stem cell transplantation. (2002) (22)
The CysLT1 Ligand Leukotriene D4 Supports α4β1- and α5β1-Mediated Adhesion and Proliferation of CD34+ Hematopoietic Progenitor Cells1 (2009) (21)
Advances in the Treatment of Testicular Cancer (2012) (21)
Autologous Followed By Allogeneic Versus Tandem-Autologous Stem Cell Transplant in Newly Diagnosed FISH-del13q Myeloma (2014) (21)
Ex vivo expansion of hematopoietic precursor cells (1996) (21)
Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet's disease with sight-threatening retinal vasculitis. (2003) (21)
Effective ex vivo generation of granulopoietic postprogenitor cells from mobilized peripheral blood CD34(+) cells. (2000) (21)
In vivo biology and therapeutic potential of hematopoietic growth factors and circulating progenitor cells. (1992) (20)
Shared Cell Surface Marker Expression in Mesenchymal Stem Cells and Adult Sarcomas (2013) (20)
Correlations between hematopoietic progenitor cell counts as measured by Sysmex and CD34+ cell harvest yields following mobilization with different regimens (2002) (20)
Impact of surgery in patients with metastatic soft tissue sarcoma: A monocentric retrospective analysis (2018) (20)
Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL. (2017) (20)
Analysis of anti–topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation (2016) (20)
Aprepitant as Salvage Therapy in Patients with Chemotherapy-Induced Nausea and Emesis Refractory to Prophylaxis with 5-HT3 Antagonists and Dexamethasone (2006) (20)
Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial (2015) (20)
Haploidentical transplant in patients with myelodysplastic syndrome. (2017) (19)
Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide (2009) (19)
CMV Infection in Bone Marrow and Solid Organ Transplant Patients in the Era of Antiviral Prophylaxis. (2000) (19)
Assessment of keratoconjunctivitis sicca in patients with fibromyalgia: results of a prospective study (1999) (19)
Complete Remission of Third Recurrence of Acute Myeloid Leukemia after Treatment with Imatinib (STI-571) (2003) (19)
Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini (2016) (19)
Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters (2005) (19)
Pregnancy after Successful Cancer Treatment: What Needs to Be Considered? (2012) (19)
Hematopoietic stem cells : biology and transplantation (1999) (19)
Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy (2001) (18)
Effective ex vivo generation of megakaryocytic cells from mobilized peripheral blood CD34(+) cells with stem cell factor and promegapoietin. (2000) (18)
Evaluation of the Murex CMV DNA Hybrid Capture assay (version 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogeneic stem cell transplant (2001) (18)
Recent strategies for the use of paclitaxel in the treatment of urological malignancies (1998) (18)
Low Tigecycline Concentrations in the Cerebrospinal Fluid of a Neutropenic Patient with Inflamed Meninges (2010) (18)
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation (2019) (18)
Epstein–Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma (2008) (18)
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: a mature follow-up report. (1999) (18)
The Monoclonal Antibody W7C5 Defines a Novel Surface Antigen on Hematopoietic Stem Cells (2001) (18)
Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns (2016) (18)
Fibrinogen gamma-chain mRNA is not detected in human megakaryocytes. (1991) (18)
Dendritic Cell‐Based Vaccines in Patients with Hematological Malignancies (2001) (18)
Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer (2009) (18)
Lymphokine(s) from isolated T lymphocyte subpopulations support multilineage hematopoietic colony and megakaryocytic colony formation. (1986) (18)
Differential Effects of G Protein–Coupled Receptors on Hematopoietic Progenitor Cell Growth Depend on their Signaling Capacities (2007) (18)
Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study (2003) (17)
Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation. (2019) (17)
Graft versus self (GvS) against T-cell autoantigens is a mechanism of graft–host interaction (2016) (17)
Influence of age on outcome after allogeneic hematopoietic cell transplantation: a single center study in patients aged ⩾60 (2015) (17)
Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis (2010) (17)
Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. (1998) (17)
The G protein-coupled receptor CysLT1 mediates chemokine-like effects and prolongs survival in chronic lymphocytic leukemia (2012) (17)
Effect of FLT3 Inhibition on Normal Hematopoietic Progenitor Cells (2007) (16)
Assessment of the composition of bone marrow prior to and following autologous BMT and PBSCT by magnetic resonance (1996) (16)
Acquired coagulopathy caused by intoxication with the superwarfarin‐type anticoagulant rodenticide flocoumafen (2011) (16)
MOLECULAR PATHOGENESIS OF EPSTEIN-BARR VIRUS ASSOCIATED POSTTRANSPLANT LYMPHOMAS: NEW INSIGHTS THROUGH LATENT MEMBRANE PROTEIN 1 FINGERPRINTING1 (2001) (16)
Purging of peripheral blood progenitor cells. (1996) (16)
Analysis of human hemopoietic progenitor cells for the expression of glycoprotein IIIa. (1988) (16)
Interstrain variation of immediate early DNA sequences and glycoprotein B genotypes in cytomegalovirus clinical isolates (1997) (16)
PCR-Based Liposomal Amphotericin B Treatment Following Allogeneic Stem Cell Transplantation Is a Safe Treatment Strategy: Preliminary Results of a Prospective Study. (2004) (16)
Culture-Expanded Human Invariant Natural Killer T Cells Suppress T-Cell Alloreactivity and Eradicate Leukemia (2018) (16)
G-CSF in the long-term treatment of cyclic neutropenia and chronic idiopathic neutropenia in adult patients. (1995) (16)
Treatment of familial Mediterranean fever with anakinra in patients unresponsive to colchicine (2017) (15)
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment (2012) (15)
Antisignal recognition particle-positive polymyositis successfully treated with myeloablative autologous stem cell transplantation (2009) (15)
Cyclosporine and renal prostaglandin E2 production. (1985) (15)
Human iPSC-based model of severe congenital neutropenia reveals elevated UPR and DNA damage in CD34+ cells preceding leukemic transformation. (2019) (15)
Reduction of Combined Modality Treatment Intensity in Early Stage Hodgkin’s Lymphoma: Interim Analysis of the HD 10 Trial of the GHSG. (2004) (15)
Analysis of megakaryocyte ploidy in patients with thrombocytosis. (1990) (15)
Retraction: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids (2003) (15)
Correlation analyses between CD34+ cells and clonogenic progenitors mobilized into the peripheral blood by IL‐3 + GM‐CSF following polychemotherapy in cancer patients (1992) (15)
Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib. (2005) (15)
Cryobiopsy increases the EGFR detection rate in non-small cell lung cancer. (2020) (15)
Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation—a phase II study (2002) (15)
Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation (2017) (15)
Phase I study of gefitinib in combination with oxaliplatin and weekly 5-FU/FA (FUFOX) for second-/third-line treatment in patients (pts) with metastatic colorectal cancer (CRC) (2005) (14)
Prediction of Molecular Response of Chronic Phase CML Patients by the EUTOS Score: Results of the Randomized CML-Study IV, (2011) (14)
Expansion of stem and progenitor cells. (1998) (14)
Myeloablative immunosuppressive treatment with autologous haematopoietic stem cell transplantation in a patient with psoriatic arthropathy and monoclonal gammopathy of undetermined significance (2004) (14)
Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA (2018) (14)
G‐CSF administration prior to donor lymphocyte apheresis promotes anti‐leukaemic effects in allogeneic HCT patients (2019) (14)
Effect of Tyrosine Kinase Inhibition Using Imatinib on Normal Lymphohematopoietic Cells (2005) (14)
186Rhenium-labeled anti-CD20 antibody radioimmunotherapy followed by autologous peripheral blood stem cell transplantation in patients with relapsed or refractory non-Hodgkin lymphoma. (2004) (13)
Mitomycin C plus Infusional 5-Fluorouracil in Platinum-Refractory Gastric Adenocarcinoma: An Extended Multicenter Phase II Study (2007) (13)
Expression of RANK‐L and in part of PD‐1 on blasts in patients with acute myeloid leukemia correlates with prognosis (2016) (13)
Cytomegalovirus, Oxidative Stress and Inflammation as Interdependent Pathomechanisms: Need for Novel Therapeutic Strategies? (1998) (13)
Molecular and Cytogenetic Response After 3 Months of Imatinib Treatment Is Predictive for the Risk of Disease Progression and Death in Newly Diagnosed Chronic Myeloid Leukemia Patients – a Follow-up Analysis of the German CML Study IV (2011) (13)
Disease progression and defects in primary hemostasis as major cause of bleeding in multiple myeloma (2020) (13)
Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT (2017) (13)
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report. (1999) (13)
Articular involvement in patients with relapsing polychondritis (1998) (13)
Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG). (1999) (13)
Enteric-coated mycophenolate sodium for progressive systemic sclerosis—a prospective open-label study with CT histography for monitoring of pulmonary fibrosis (2013) (13)
Combination of cytokines: current status and future prospects (1991) (13)
GM-CSF treatment is not effective in congenital neutropenia patients due to its inability to activate NAMPT signaling (2017) (12)
Progressive multifocal leukoencephalopathy (2003) (12)
[Diabetes, insulin, insulin analogues, and cancer]. (2010) (12)
The Use of Interferon-α in Behçet’s Disease — Review of the Literature and Possible Mechanisms of Action (2004) (12)
Fever and increasing cANCA titre after kidney and autologous stem cell transplantation for Wegener’s granulomatosis (2005) (12)
Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group (2002) (12)
Detection of messenger RNAs within single hemopoietic cells by in situ hybridization on small slide areas. (1988) (12)
High‐grade lymphoma mimicking bone crisis in Gaucher's disease (2001) (12)
Management of Cytomegalovirus Infection after Solid-Organ or Stem-Cell Transplantation (2012) (12)
Phase II study of continuous 120-hour-infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent gastrointestinal adenocarcinoma. (2000) (12)
Intracerebroventricular delivery of self-complementary adeno-associated virus serotype 9 to the adult rat brain (2016) (12)
Treatment of Patients up to 60 Years with High Risk AML: Final Results of the AML SHG-Hannover 01/99 Trial. (2006) (12)
Peripheral blood stem cells: In vivo biology and therapeutic potential (1994) (11)
Extended in vitro expansion of adult, mobilized CD34+ cells without significant cell senescence using a stromal cell coculture system with single cytokine support. (2009) (11)
Identification of human megakaryocytes derived from pure megakaryocytic colonies (CFU-M), megakaryocytic-erythroid colonies (CFU-M/E), and mixed hemopoietic colonies (CFU-GEMM) by antibodies against platelet associated antigens (1982) (11)
Progressive multifocal leukoencephalopathy: cidofovir therapy in three patients with underlying hematological disease. (2003) (11)
Lower limb pitting edema in systemic lupus erythematosus (1999) (11)
Osteoprotegerin positively regulates hematopoietic progenitor cells. (2012) (11)
Symptomatic hypoglycemia during imatinib mesylate in a non-diabetic female patient with gastrointestinal stromal tumor (2007) (11)
Regulation of FLT3 and its ligand in normal hematopoietic progenitor cells (2009) (11)
Cytotoxic T-cell clones derived from pluripotent stem cells (CFU-GEMM) of patients with Hodgkin's lymphoma. (1982) (11)
Nonpeptide Mediators in the Hematopoietic Microenvironment (2003) (11)
Reduced-intensity conditioning with fludarabine and busulfan for allogeneic hematopoietic cell transplantation in elderly or infirm patients with advanced myeloid malignancies (2015) (10)
The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors (2004) (10)
A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and “pan-leukemia” antigens (2017) (10)
Treatment of Adult Patients with High Risk Acute Myeloblastic Leukemia up to 60 Years: Role of Consolidation Therapy within a Prospective Multicenter Trial. (2004) (10)
Expression of Laminin β2 Chain in Normal Human Bone Marrow (1999) (10)
Granulocyte colony-stimulating factor induced pulmonary hemorrhage in a healthy stem cell donor. (2007) (10)
Fluorescence-activated sorting of individual cells onto poly-L-lysine-coated slide areas. (1986) (10)
Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma. (2006) (9)
Hypersensitivity pneumonitis associated with the use of trofosfamide. (2004) (9)
Relapse of primary CNS lymphoma after more than 10 years in complete remission (2005) (9)
Long-term disease stabilization during second-line gemcitabine in a refractory metastatic haemangioendothelioma. (2009) (9)
final Results From A Phase 1 Study Of Blinatumomab In Patients With Relapsed/refractory Non-hodgkin's Lymphoma : 302 (2013) (9)
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: Update on the Survival Outcome Following Allogeneic HSCT after Imatinib Failure; Results of the German CML Study IV (2008) (9)
[Interferon-alpha-associated polyarthritis. Possible induction of seropositive rheumatoid arthritis by interferon-alpha: two case reports and review of the literature]. (1999) (9)
Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote ex vivo Lysis of Leukemic Blasts in a CD1d-Dependent Manner (2019) (9)
Leflunomide and peripheral neuropathy: A potential interaction between uracil/tegafur and leflunomide (2005) (9)
Death Receptor Expression on Blasts in AML Is Associated with Unfavorable Prognosis. (2015) (9)
Weekly short infusions of gemcitabine are not associated with suppression of lymphatic activity in patients with solid tumors. (1997) (9)
Peripheral blood cell telomere length measurements indicate that hematopoietic stem cell turnover is not significantly increased in whole blood and apheresis PLT donors (2003) (9)
Induction of minor histocompatiblity antigen HA-1-specific cytotoxic T cells for the treatment of leukemia after allogeneic stem cell transplantation. (1999) (8)
Sorafenib but not sunitinib affects the induction of immune responses (2007) (8)
Disseminated Epitheloid Hemangioendothelioma Mimicking Symptoms of Systemic Vasculitis (2005) (8)
Diagnosis and Treatment of Patients with Testicular Germ Cell Cancer (1999) (8)
Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies (2017) (8)
The role of autologous stem cell transplantation in peripheral T cell lymphoma: a long-term follow-up single-center experience (2019) (8)
Expression of 4-1BB and its ligand on blasts correlates with prognosis of patients with AML (2016) (8)
T‐cell–depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia: A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT) (2018) (8)
Future prospects in the chemotherapy of metastatic nonseminomatous testicular germ-cell cancer (1999) (8)
Loss of NFAT2 expression results in the acceleration of clonal evolution in chronic lymphocytic leukemia (2019) (8)
Paraneoplastic granulocyte colony-stimulating factor secretion in soft tissue sarcoma mimicking myeloproliferative neoplasia: a case report (2014) (8)
Allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia and pulmonary mucormycosis (2012) (8)
53 A phase I study of epidermal growth factor receptor (EGFR) antibody EMD 72000 in combination with paclitaxel (P) in patients (pts) with EGFR-positive advanced non-small cell lung cancer (NSCLC) (2003) (8)
Fatal immune-mediated pancytopenia and a TRALI-like syndrome associated with high titers of recipient-type antibodies against donor-derived peripheral blood cells after allogeneic bone marrow transplantation following dose reduced conditioning. (2004) (8)
Prognostic factors in patients (pts) with advanced metastatic seminoma (SEM) treated with either single agent carboplatin (CP) or cisplatin-based (DDP) combination chemotherapy (CTX): a meta-analysis of prospective European trials. (2002) (7)
Characterization of Purified and Ex Vivo Manipulated Human Hematopoietic Progenitor and Stem Cells in Xenograft Recipients (1999) (7)
Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab (2016) (7)
The use of interferon-alpha in Behçet's disease--review of the literature and possible mechanisms of action. (2003) (7)
Secondary Malignancies in CML Patients – Data From the German CML Study IV (2012) (7)
Unusual leukemia presentations. Case 1. Pulmonary chloroma preceded by leukemia cutis 7 years earlier. (2005) (7)
R-CHOP VERSUS R-FC FOLLOWED BY MAINTENANCE WITH RITUXIMAB OR IFN (2011) (7)
The influence of gemcitabine on the CD4/CD8 ratio in patients with solid tumours. (1997) (7)
Molecular recognition patterns of anti-topoisomerase I-antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation. (2018) (7)
Haematopoietic growth factors and peripheral blood stem cells as supportive agents in dose intensification. (1993) (7)
The use of hematopoietic growth factors for high-dose chemotherapy and peripheral blood progenitor cell transplantation. (1994) (7)
Activity of gemcitabine in platinum-resistant ovarian germ cell cancer. (1996) (7)
Invariant natural killer T cells are functionally impaired in patients with systemic sclerosis (2019) (7)
Human megakaryocytic progenitor cells (1987) (7)
Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil (2004) (7)
Identification of B cells in multilineage hematopoietic colonies derived from cells of patients with lymphocytic lymphoma. (1985) (7)
Superior CMR-Rates with Tolerability-Adapted Imatinib 800 Mg Vs. 400 Mg Vs. 400 Mg + IFN In CML: The Randomized German CML-Study IV (2010) (7)
HD12 Randomised Trial Comparing 8 Dose-Escalated Cycles of BEACOPP with 4 Escalated and 4 Baseline Cycles in Patients with Advanced Stage Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Lymphoma Study Group (GHSG), University of Cologne, D-50924 Cologne, Germany. (2006) (7)
First-Line High-Dose Chemotherapy for ’Poor Risk’ Metastatic Non-Seminomatous Testicular Germ Cell Tumors (1998) (7)
Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation (2016) (6)
Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia (2018) (6)
T-cell depletion with ricin A-chain T101 in allogeneic bone marrow transplantation to prevent severe graft-versus-host disease. (1988) (6)
Rituximab and leflunomide for Wegener’s granulomatosis: a long-term follow-up (2011) (6)
Management of Invasive Fungal Infections in Oncological Patients (1999) (6)
First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications (2018) (6)
Immune Reconstitution after Haploidentical Hematopoietic Cell Transplantation: Impact of Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts (2008) (6)
Meeting Report: Primary Central Nervous System Lymphoma: Standards Of Care And Future Perspectives (2005) (6)
Vaccinations with RNA coding for tumor associated antigens in advanced RCC patients—A phase I/II study (2008) (6)
The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia (2017) (6)
High-dose chemotherapy with autologous peripheral blood stem cell transplantation for metastatic gastric leiomyosarcoma (1997) (6)
Behçet's disease in patients of German and Turkish origin--a comparative study. (2003) (6)
Hemopoietins in Clinical Oncology (1991) (6)
Neo-adjuvant high-dose chemotherapy with autologous peripheral blood stem cell transplantation for inoperable relapse of nuchal liposarcoma resistant to standard-dose chemotherapy. (1996) (6)
Comorbidity, Measured By The Charlson Index, Has No Negative Impact On Remission In Patients With Chronic Myeloid Leukemia: Results Of The Randomized CML-Study IV (2013) (6)
Gene expression profiling of normal hematopoietic progenitor cells under treatment with imatinib in vitro (2005) (6)
Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell support. (2003) (6)
Role of hematopoietic growth factor combinations in experimental and clinical oncology. (1992) (6)
Intravascular lymphoma - a rare cause of hemolytic anemia and neurologic disorders. (2004) (5)
Optimizing Early Prediction Of Outcome In CML Using The Exact Decline Of BCR-ABL Transcript Levels Within 3 Months Of Imatinib Treatment As a Prognostic Marker (2013) (5)
Ex vivo manipulation of hematopoietic stem and progenitor cells (1998) (5)
Bone marrow carcinosis in breast cancer: Clinical presentation, treatment, and prognosis--A single institution review of 22 cases. (2010) (5)
Ventricular thrombus and thrombocytopenia as first presentation of anaplastic thyroid carcinoma. (2013) (5)
Purging of peripheral blood progenitor cell autografts and treatment of minimal residual disease (1997) (5)
[The MR characterization of the composition of the hematopoietic bone marrow. The findings in generalized neoplasms and the monitoring of therapy]. (2000) (5)
Definition and Characterization of a Peptide Warehouse for the Patient-Individualized Peptide Vaccination Study (iVAC-L-CLL01) after First Line Therapy of CLL (2017) (5)
Low plasma protein Z levels are associated with an increased risk for perioperative bleedings (2018) (5)
Secretion of Colony-Stimulating Factor for Macrophages (M-CSF) and Granulocyte/Macrophages (GM-CSF) is Developmentally Regulated in Human Macrophages (1990) (5)
Megakaryocytic colony-stimulating activity in patients receiving a marrow transplant during hematopoietic reconstitution. (1988) (5)
Optimaization of Imatinib Therapy by Combination. 5 Year Survival and Response Results of the Pilot Phase of the Randomized German CML STUDY IV. (2009) (5)
Treatment Associated Interstitial Pulmonary Toxicity of Temozolomide Plus Bevacizumab for Locally Advanced Solitary Fibrous Tumor (2016) (5)
The role of cytokines in oncology. (1991) (5)
Complete Molecular Remission (CMR 4.5) of CML Is Induced Faster by Dose – Optimized Imatinib and Predicts Better Survival - Results From the Randomized CML-Study IV (2012) (5)
[Late toxicity after chemotherapy of malignant testicular tumors]. (1998) (5)
Interference of a human leukocyte interferon preparation with stimulatory activities in leukocyte-conditioned medium for human hematopoietic stem cells. (1984) (5)
The management of primary mediastinal B-cell lymphoma with sclerosis. (1994) (5)
Clinical Trials with Haematopoietic Growth Factors and Peripheral Blood Stem Cells (1992) (5)
Potential role of cysteinyl leukotrienes in trafficking and survival of hematopoietic progenitor cells. (2003) (5)
The Effects of Induction Chemotherapy and High-Dose Melphalan with Tandem Autologous Transplantation in Multiple Myeloma: The Prospective Randomized DSMM 2 Study. (2007) (5)
Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers (2018) (5)
Follow‐up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation (2017) (5)
Interaction of 3-deaza-adenosine, a phospholipid methyltransferase inhibitor, on the production of pluripoietins from human peripheral T cells. (1985) (5)
New Aspects for the Diagnosis of Invasive Fungal Disease in Oncological Patients (1997) (5)
NK-Cell Recovery and Immune Reconstitution after Haploidentical Hematopoietic Cell Transplantation Using Either CD34 Selected Grafts and Adoptive NK-Cell Transfer or CD3/CD19 Depleted Grafts: Comparison of Two Strategies for NK Cell Based Immunotherapy. (2007) (5)
Molecular methods in the diagnosis of infections in the immunocompromised host (2000) (5)
153 Samarium-EDTMP in myeloablative dosage followed by a second autotransplantation in patients with relapsed multiple myeloma. (2004) (4)
Should whole-brain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lymphoma? The G-PCNSL-SG1 randomized phase IV trial. (2010) (4)
Allogeneic Hematopoietic Cell Transplantation in AML: Comparable Results After Matched or Mismatched Unrelated Versus Matched Related Transplantation. (2009) (4)
Influence of interferon-alpha on lymphocyte subpopulations in Behçet's disease. (2003) (4)
Adjuvant radiochemotherapy (RTx/CTx) using 5-FU/Folinic acid (FA) /cisplatin (DDP) {+/-} paclitaxel (P) and radiation in patients (pts) with completely (R0) resected high-risk gastric cancer (UICC stages II-IV (M0): An extended phase II study of the AIO/ARO/ACO (2004) (4)
Gain-of-Function KIT Mutations Sensitize the Mutant Isoform to the Type I Tyrosine Kinase Inhibitor Crenolanib: A Rationale for the Therapeutic Use in Systemic Mastocytosis (SM) and Core Binding Factor Leukemias (CBFL) (2014) (4)
Elimination Of Minimal Residual Disease (MRD) In AML Patients With a Novel Fc-Optimized FLT3 Antibody (4G8-SDIEM) (2013) (4)
Adverse Events (AE) Under Imatinib Treatment Over 10 Years: Results From 1501 Patients Of The Randomized CML-Study IV (2013) (4)
[Severe hemorrhage in a patient with metastatic colorectal cancer - case 8/2012]. (2012) (4)
Allogene Stammzelltransplantation (1999) (4)
Publisher Correction: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion (2019) (4)
A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors. (2002) (4)
HLA Ligandome Analysis Of Chronic Myeloid Leukemia (CML), Revealed Novel Tumor Associated Antigens For Peptide Based Immunotherapy (2013) (4)
Allogeneic hematopoietic cell transplantation in patients ⩾70 years: which patients may benefit? (2016) (4)
[Allogeneic transplantation of stem cells]. (1999) (4)
Soluble heat shock protein 70 members in patients undergoing allogeneic hematopoietic cell transplantation. (2016) (4)
Late Consolidation for Patients with Standard Risk AML up to 60 Years: Results of a Prospective Randomized Comparison of High Dose AraC and Autologous PBSCT. (2004) (4)
Retraction: reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. (2001) (4)
Intravenously administered rituximab induces remission of EBV associated non Hodgkin lymphoma confined to the brain in a patient after allogeneic stem cell transplantation. (2006) (4)
Results of a Phase II Study of Haploidentical Hematopoietic Cell Transplantation (HHCT) in Adults Using Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts: Clinical Outcome and Immune Reconstitution. (2009) (4)
Fertility Preservation in Young Female Lymphoma Patients: Review of Available Options and Initial Experiences with Their Implementation in Clinical Routine (2011) (4)
HLA Ligandome Analysis of Primary Chronic Lymphocytic Leukemia (CLL) Cells Under In Vitro Lenalidomide Treatment Confirms Lenalidomide as a Suitable Combination Partner for T-Cell Based Immunotherapy (2016) (4)
Expression of laminin beta2 chain in normal human bone marrow. (1999) (4)
Haematopoietic growth factors in clinical medicine. (1994) (4)
Choroidal metastases from thymic carcinoma during pregnancy: Case Report (2015) (4)
[Diagnostic criteria in polycythemia vera]. (1998) (3)
Induction of NK Cell Reactivity Against Myeloid Leukemia By a Novel Fc-Optimized CD133 Antibody (2015) (3)
Comparing the Prognostic Significance of Early Predictors of Survival in Chronic Myeloid Leukemia (CML) Treated with Imatinib - an Analysis of the Randomized CML-Study IV (2014) (3)
Severe acute graft-versus-host disease after T-cell depleted allogeneic stem cell graft from a second donor caused by persisting T-cells from the first donor (2003) (3)
Primary malignant sarcomas of the heart and great vessels - a single center experience. (2004) (3)
Anti-infective prophylaxis with aciclovir and cotrimoxazole to reduce the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy. (2017) (3)
Mobilization of peripheral blood progenitor cells by hemopoietic growth factors following standard dose chemotherapy (1992) (3)
Allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A single center experience (2016) (3)
CONCISE COMMUNICATIONS Cytomegalovirus Monitoring by Polymerase Chain Reaction of Whole Blood Samples from Patients Undergoing Autologous Bone Marrow or Peripheral Blood Progenitor Cell Transplantation (1997) (3)
Coating of Tumor Cells by Platelets Confers Expression of Immunoregulatory Molecules Which Impair NK Cell Anti-Tumor Reactivity. (2009) (3)
A Randomized Comparison of Total-Marrow Irradiation, Busulfan and Cyclophosphamide with Tandem High-Dose Melphalan in Patients with Multiple Myeloma. (2007) (3)
A GRAFT ENGINEERING METHOD TO ALLOW BONE MARROW TRANSPLANTATION (BMT) FOR MORE HIGHLY MISMATCHED RECIPIENTS WITH LEUKEMIA: MULTIVARIATE ANALYSIS OF A PHASE I/II PROTOCOL.: Abstract# 702 (2000) (3)
Matched Unrelated Donor Stem Cell Transplantation for Patients with Diffuse Large Cell B Cell Lymphoma: A Retrospective Analysis of 118 Patients Registered through the European Group for Blood and Marrow Transplantation (EBMT). (2006) (3)
Cooperating, congenital neutropenia–associated Csf3r and Runx1 mutations activate pro-inflammatory signaling and inhibit myeloid differentiation of mouse HSPCs (2020) (3)
Long-term remission of refractory Rosai-Dorfman disease after salvage therapy with clofarabine in an adult patient (2018) (3)
Anti-infective prophylaxis with aciclovir and cotrimoxazole significantly reduces the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy (2017) (3)
Allogene Stammzelltransplantation bei Akuter Myeloischer Leukämie und HIV-Infektion – Fall 3/2012 (2012) (3)
Late toxicity after treatment for testicular germ cell cancer (1998) (3)
Mobilization, purification and ex vivo expansion of human peripheral blood progenitor cells. (1993) (3)
Sustained remission of an extensive monoclonal, Epstein-Barr virus-associated diffuse large B cell lymphoma in a kidney-pancreas transplant recipient (2002) (3)
Complete remission after myeloablation with bone-seeking 186Re-HEDP and high-dose melphalan followed by autologous stem cell transplantation in a patient with chemorefractory multiple myeloma (2005) (3)
Long-term results after transplantation of CD34+ selected (CellPro) versus unselected peripheral blood progenitor cells (PBPC) from related allogeneic donors (2010) (3)
[Current value of stem-cell transplantation in autoimmune diseases]. (2008) (3)
Eight Cycles of Escalated-Dose BEACOPP Compared With FourCycles of Escalated-Dose BEACOPP Followed by Four Cycles ofBaseline-Dose BEACOPP With or Without Radiotherapy in PatientsWith Advanced-Stage Hodgkin’s (2011) (3)
Time-Related Interpretation of Molecular Response Levels According to Long Term Overall and Progression-Free Survival of CML Patients on First-Line Imatinib Treatment (2011) (3)
Severe Impairment of Dendritic Cell Allostimulatory Activity by Sendai Virus Vectors Is Overcome by Matrix Protein Gene Deletion. (2005) (3)
Involvement of NFAT Transcription Factors in NK Cell Reactivity (2016) (3)
5-Azacytosine (Azacytidine) and 2′-Deoxy-5-Azacytidine (Decitabine) Mediate Opposite Effects on NK Cell Anti-Tumor Reactivity (2008) (3)
Cardiac Myeloid Sarcoma: Multimodality Radiologic Imaging Features and Pathologic Correlation. (2016) (3)
Treatment of ocular Behcet's disease (BD) with recombinant human interferon-alpha 2a (rhIFN-alpha 2a) - A three center pilot study (1998) (3)
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer. (1997) (2)
Upregulation of Osteoactivin Upon Exposure to Tyrosine Kinase Inhibitors Impairs the T Cell Stimulatory Capacity of Monocyte-Derived Dendritic Cells (2011) (2)
A randomized trial comparing the toxicity and the treatment costs of HD-VIC plus PBSC transplantation with or without amifostine (AMI) in patients with solid tumors (1999) (2)
Efficacy Analysis of the Novel Dual PI3K-MTORC1/2 Inhibitors NVP-BGT226 and NVP-BEZ235 in Acute Leukemia. (2012) (2)
A modified culture system for multilineage hematopoietic progenitors (CFU-GEMM) (1984) (2)
Suppressor T-cell clones derived from pluripotent stem cells (CFU-GEMM) of a patient with hodgkin's lymphoma (1982) (2)
Ex vivo manipulations of CD34+ peripheral blood progenitor cells. (1996) (2)
Absence of NKG2D Ligands Defines Human Acute Myeloid Leukaemia Stem Cells and Mediates Their Immune Evasion (2018) (2)
Regulation of CXCR1, CXCR2 and CXCR4 in Human Neutrophils: Potential Role in the Release from the Bone Marrow, Clearance of Senescent Cells, and Cell Function at Sites of Inflammation. (2005) (2)
Interleukin-3 and granulocyte-macrophage colony-stimulating factor in combination: clinical implication. (1992) (2)
Long Term Remission in Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL) with Rituximab Consolidation after High-Dose Chemotherapy and Autologous Stem Cell Transplantation: Extended Follow-Up of a Multicenter Phase II Study. (2005) (2)
The FLT3-Inhibitors Midostaurin, Sunitinib, Sorafenib, and TKI258 Differentially Affect NK Cell-Mediated Immunesurveillance of Acute Myeloid Leukemia. (2009) (2)
Follow up after primary treatment: curable diseases treated non-surgically. (2000) (2)
Absence Of Human Herpesvirus 8 Dna Sequences In Leucapheresis Products And Bone Marrow Samples Of Patients With Advanced Multiple Myeloma (2000) (2)
[High dose therapy and stem cell transplantation. A new path in tumor therapy]. (1997) (2)
Platelet-Derived Proteases ADAM10 and ADAM17 Impair NK Cell Immunosurveillance of Metastasizing Tumor Cells By Diminishing NKG2D Ligand Surface Expression (2014) (2)
Therapy with Imatinib In Elderly CML Patients (>65years): Results of the German CML-Study IV. (2010) (2)
Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era. (2014) (2)
Hierarchy of Human B Cell Regeneration after Rituximab Therapy. (2006) (2)
Second Line Therapy with Second Generation TKI After Intolerance to Imatinib Based Treatments Showed High Overall Survival in Contrast to Second Line Therapy After Resistance; Results of the Randomized CML Study IV (2011) (2)
Human megakaryocytic colony formation is supported by lymphokines from isolated T-lymphocyte subpopulations. (1986) (2)
In Vivo Effects of Interleukin-6 and Leukemia Inhibitory Factor on Thrombopoiesis in Primates (1992) (2)
Platelets Impair NK Cell Immunosurveillance Of Metastasizing Tumor Cells By Altering Surface Expression and Shedding Of Ligands For The Activating Immunoreceptor NKG2D (2013) (2)
relapsed or refractory non-Hodgkin lymphoma with by autologous peripheral blood stem cell transplantation in patients 186Rhenium-labeled anti-CD20 antibody radioimmunotherapy followed (2013) (2)
Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma—a long-term follow-up single center experience (2020) (2)
Clinical role of colony stimulating factors. (1991) (2)
Novel Markers for the Isolation of Primary Bone Marrow Derived MSC with Multi-Lineage Differentiation Capacity. (2006) (2)
Neutralization of Tumor-Derived Soluble Glucocorticoid-Induced TNF-Related Protein (GITR) Ligand Present in Cancer Patient Sera Increases Anti-Tumor Reactivity of NK Cells. (2007) (2)
IL-3 plus GM-CSF Induced Recruitment of High Numbers of Peripheral Blood Progenitor Cells Following Standard Dose Chemotherapy (1993) (2)
Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML (2020) (2)
Thymic findings before and after autologous stem cell transplantation for severe systemic sclerosis: a retrospective study using computed tomography in the pre- and post-transplantation setting. (2017) (2)
UFT/calcium folinate plus weekly paclitaxel for solid tumors. (1999) (2)
Functional Characterization of Signaling Events Underlying Immunostimulatory and Immunosuppressive Activity of Macrophages. (2008) (2)
NK Cell Anti-Tumor Reactivity Is Impaired by Platelet-Derived TGF-B through NKG2D Downregulation (2008) (2)
Aprepitant as salvage therapy in patients (pts) with chemotherapy (ctx)- induced nausea and emesis (n/v) refractory to prophylaxis with 5-HT3-antagonists and dexamethasone (dexa) (2005) (2)
The HIV protease inhibitor ritonavir and the proteasome inhibitor bortezomib induce synergistic cytotoxicity on soft tissue sarcoma cells in vitro. (2006) (2)
Hematopoietic stem cells (2005) (2)
Impact of Balanced or Unbalanced Karyotype At Diagnosis On Prognosis of CML: Long-Term Observation From 1346 Patients of the Randomized CML Study IV (2012) (2)
Induction of clinical and immunological responses in patients with metastatic renal cell carcinoma after vaccinations with peptide pulsed dendritic cells (2005) (2)
Early high-dose chemotherapy and peripheral blood progenitor cell transplantation in limited-disease small-cell lung cancer. Results of a single center phase II study (1997) (2)
Matrilysin (MMP-7) Is a Novel Broadly Expressed Tumor Antigen Recognized by Antigen-Specific T Cells. (2007) (2)
RECONSTITUTION OF HEMATOPOIESIS AFTER BONE MARROW PURGING WITH RICIN A CHAIN IMMUNOTOXIN (1986) (2)
Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging. (2001) (2)
Sustained complete remission of recurrent acute myeloid leukaemia with a single dose of gemtuzumab ozogamicin and low-dose interleukin-2 maintenance (2002) (2)
Long-term effects of testicular cancer treatment on sexual functioning (1997) (2)
Clinical Impact of TERT A1062T Mutations in Younger Patients with Acute Myeloblastic Leukemia (2012) (2)
Adjuvant radiochemotherapy (RTx/CTx) using 5-FU/Folinic acid (FA) /cisplatin (DDP) ± paclitaxel (P) and radiation in patients (pts) with completely (R0) resected high-risk gastric cancer (UICC stages II-IV (M0): An extended phase II study of the AIO/ARO/ACO. (2004) (2)
Haploidentical Allogeneic Hematopoietic Cell Transplantation in Adults Using Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts: Interim Analysis of a Phase I/II Study. (2008) (2)
[Current aspects of adjuvant and palliative chemotherapy in colorectal carcinoma]. (1997) (2)
[56-year-old patient with leg paresis, pulmonary infiltrates, and eosinophilia--Case 08/2009]. (2009) (2)
Inhibition of the NAMPT-Triggered Deacetylation of HCLS1 Protein: A New Therapeutic Option in Chronic Myeloid Leukemia (2015) (2)
ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10-YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV (2017) (2)
B-cell depletion in patients with rheumatoid arthritis refractant to multiple TNF blockers and the interleukin 1 receptor-antagonist anakinra (2007) (2)
Single High-Dose Chemoradiotherapy Versus Tandem High Dose Melphalan Followed by Auto-SCT for Advanced Multiple Myeloma. Preliminary Analysissis. (2004) (2)
management and outcome of Cml-blast crisis: Results from the randomized Cml study Iv : V907 (2014) (2)
Collagenous colitis associated with rheumatoid arthritis and anticardiolipin antibodies (2005) (2)
Dose Reduced Conditioning and CD3/CD19 Depletion for Haploidentical Allogeneic Hematopoietic Cell Transplantation in Adults: Fast Engraftment and Low Toxicity. (2005) (2)
Development and Preclinical Characterization of an Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity Against Myeloid Leukemia (2014) (2)
Defining Therapy Goals for Major Molecular Remission in Chronic Myeloid Leukemia: Results of the Randomized CML-Study IV (2014) (1)
C-Cbl Regulates c-Mpl Receptor Trafficking and Its Internalization (2015) (1)
Consequences of 4-1BB-4-1BB Ligand Interaction for NK Cell Anti-Tumor Immunity: Opposite Effects of Seemingly Analogue Molecules in Mice and Men. (2009) (1)
FLT3 and KIT Isoforms Activate PI3K/AKT Signaling Which Is Potently Blocked by the Novel Dual PI3K/Mtor Inhibitors NVP-BEZ235 and NVP-BGT226. (2009) (1)
Human Recombinant for the Treatment of Behçet's Disease with Sight- Threatening Retinal Vasculitis (2003) (1)
10-year survival with imatinib: final evaluation of randomized CML-study (2017) (1)
Distinct Characteristics of e13a2 versus e14a2 BCR-ABL Chronic Myeloid Leukemia under Upfront Treatment with Imatinib – an Analysis of the German CML Study IV, (2011) (1)
Time Course of Acquisition of a CSF3R Mutation and Subsequent Development of AML in a Patient with Cyclic Neutropenia (2015) (1)
Studies of Interferon as a Regulator on Hematopoietic Stem Cells in Chronic Myelogenous Leukemia (1988) (1)
Genetic Loss of NFAT2 Induces Profound Acceleration of CLL in the TCL1 Mouse Model (2012) (1)
Living donor APOLT-ALPPS : paradigm shift in the management of irresectable colorectal liver metastases (2019) (1)
Identification and Characterization of HLA Class I-Restricted MYD88 L265P-Derived Peptides As Tumor-Specific Targets for Immunotherapy (2015) (1)
Epitope spreading occurs in cancer patients after vaccination with a single tumor antigen (2000) (1)
Fc-Engineered NKG2D-IgG1 Fusion Proteins Target Leukemia Cells for Antibody-Dependent Cellular Cytotoxicity (ADCC) of NK Cells (2011) (1)
Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia (2000) (1)
Faster Engraftment and Immune Reconstitution after Haploidentical Allogenic Hematopoietic Cell Transplantation with CD3/CD19 Depleted as Compared to CD34 Selected Grafts. (2005) (1)
The German PID-net registry (2017) (1)
Aberrant NFAT2 signaling in chronic lymphocytic leukemia. (2013) (1)
The role of Cdx2 in human leukemogenesis (2013) (1)
High-dose desferoxamine and Diamond-Blackfan anemia. (1986) (1)
Late onset CMV-disease after allogeneic stem cell transplantation (1996) (1)
UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumors. (2000) (1)
Genetic Loss of NFAT2 Leads to CLL Transformation (2015) (1)
Expression of c-myc in stimulated T lymphocytes of the helper/inducer phenotype producing lymphokine(s) supporting multilineage colony formation. (1986) (1)
Selective FLT3 Inhibition Uncovers the Role of FL and FLT3 in Normal CD34+ Hematopoietic Stem Cells. (2006) (1)
Inhibition of Hypusination of Eukaryotic Initiation Factor 5a (eIF-5A) as a Novel a Synergistic Treatment Strategy in Imatinib-Treated BCR-ABL Positive Leukemias Identified by a Global Proteomics Approach. (2005) (1)
Monocyte-Derived Dendritic Cells Induce Functionally Active Regulatory T Cells Upon Exposure to BCR-ABL Tyrosine Kinase Inhibitors. (2012) (1)
Relapse of autoimmune diseases after autologous T cell depleted stem cell transplantation may be triggered by T cells recently emigrated from the thymus (2005) (1)
Myc Drives MLL Leukemogenesis in a Human CRISPR/Cas9 Leukemia Model and Indirect Inhibition with JQ1 Diminishes Leukemia Activity (2018) (1)
Mapping the HLA Ligandome Landscape of Chronic Myeloid Leukemia (CML)—Towards Peptide Based Immunotherapy (2014) (1)
Understanding the Role of CSF3R and Runx1 Runt Homology Domain Missense Mutations in Leukemic Transformation of Hematopoietic Stem Cells (2018) (1)
ANTI‐INFECTIVE PROPHYLAXIS WITH ACICLOVIR AND COTRIMOXAZOLE SIGNIFICANTLY REDUCES THE RATE OF INFECTIONS AND THERAPY‐ASSOCIATED DEATHS IN ELDERLY PATIENTS WITH DLBCL UNDERGOING R‐CHOP IMMUNOCHEMOTHERAPY (2017) (1)
RANKL Expressed by Acute Myeloid Leukemia Cells Impairs NK Cell-Mediated Immune Surveillance (2010) (1)
[Current aspects of chemotherapy of metastatic pancreatic and biliary tract carcinomas]. (2000) (1)
The fascinating life of hematopoietic stem cells (1998) (1)
Analysis of Leukemogenic Effects of RUNX1 and CSF3R Mutations Using Congenital Neutropenia (CN)/AML Patient-Derived Induced Pluripotent Stem Cells (iPSCs) (2016) (1)
Addition of Cyclophosphamide to Pomalidomide and Dexamethasone in Case of Suboptimal Response to Pomalidomide and Dexamethasone Alone in Relapsed and/or Refractory Multiple Myeloma: Results of the GMMG-Perspective Trial (2017) (1)
Meeting summary: International Symposium and Workshop on Hematopoietic Stem Cells V, University of Tübingen, Germany, September 16-18, 2004. (2005) (1)
Abstract CT057: Phase I trial to evaluate the feasibility and safety of an individualized peptide vaccine of unmodified cancer antigens: PepIVAC-01 (2018) (1)
The Mechanism of Type I Interferon-Mediated Polarization of Tumor-Associated Neutrophils in Mice and Human (2015) (1)
[Endocrine abnormalities in a young patient with metastatic cancer - case 3/2013]. (2013) (1)
Mapping the HLA Ligandome Landscape of Chronic Myeloid Leukemia Identifies Novel CD8+ and CD4+ T Cell-Epitopes for Immunotherapeutic Approaches (2016) (1)
Meeting summary: International Symposium and Workshop on Hematopoietic Stem Cells IV, University of Tübingen, Germany, September 19-21, 2002. (2001) (1)
HLA Ligandome Analysis of Acute Myeloid Leukemia (AML) Revealed Novel Tumor-Associated Antigens for Immunotherapy. (2012) (1)
Hematopoietic Progenitor Cells + Adhesion and Proliferation of CD 34-Mediated 1 β 5 α-and 1 β 4 α Supports 4 Ligand Leukotriene D 1 The CysLT (2009) (1)
Prospective Isolation of Mesenchymal Stem Cells from Human Bone Marrow and Placenta Using a Frizzled-9-Specific Monoclonal Antibody. (2006) (1)
35 Adoptive transfer of HCMV PP65 — Peptide loaded DCS to improve HCMV=specific T cell reconstitution following allogeneic stem cell transplantation (2003) (1)
Sphingosine 1-Phosphate (S1P) Is a Chemotactic Factor for CD34+ Progenitors and CD34+ Cell Lines Expressing the S1P1 Receptor: Possible Contribution to Progenitor Cell Trafficking. (2004) (1)
The Kinase Inhibitors Sunitinib (Sutent®) and Sorafenib (Nexavar®) Differentially Affect Reactivity of NK Cells Against Renal Cell Cancer. (2007) (1)
[Diagnosis and treatment of parapneumonic effusions--case 10/2009]. (2009) (1)
B cell lineage: part of the differentiation program of human pluripotent stem cells. (1985) (1)
The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34 (cid:1) progenitor cells (2004) (1)
Identification of Hypusination Inhibitors as a Novel Therapuetical Option in BCR-ABL Positive Leukemias Using a Proteomics Approach. (2004) (1)
Intradermal RNA-Vaccination of Patients with Metastatic Renal Cell Carcinoma. (2005) (1)
Her-2 / neu-derived Peptides Are Tumor-associated Antigens Expressed by Human Renal Cell and Colon Carcinoma Lines and Are Recognized by in Vitro Induced Specific Cytotoxic T Lymphocytes 1 (2006) (1)
Pseudoexpression of Glucocorticoid-Induced TNF-Related (GITR) Ligand Upon Coating of Cancer Cells by Platelets Impairs NK Cell Anti-Tumor Reactivity (2010) (1)
Correction to Supporting Information for Kowalewski et al., HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL) (2015) (1)
Epigenetic Upregulation of the O-Linked Beta-N-Acetylglucosamine Transferase (OGT) in Response to Dronabinol Results in Antileukemic Efficacy In Vivo (2015) (1)
NKG2D and Its Ligands In Leukemia: Comprehensive Analysis of Expression, Release and Modulation of NK Cell Reactivity. (2010) (1)
Restoration of nonclonal hematopoiesis in chronic myelogenous leukemia with interferon alpha (1990) (1)
Mapping The HLA Ligandome Of Chronic Lymphocytic Leukemia – Towards Peptide Based Immunotherapy (2013) (1)
BCR/ABL Inhibitors Influence Phenotype and Function of Monocyte-Derived Human Dendritic Cells. (2009) (1)
Successful haematopoietic stem cell transplantation from a matched unrelated donor following three graft failures from HLA-mismatched related donors (2003) (1)
Overexpression and Aberrant Nuclear Translocation of NFAT2 in CLL (2012) (1)
Outcome of Patients Aged ≥60 After Allogeneic Hematopoietec Cell Transplantation: Age Has No Impact on Survival (2010) (1)
ectonucleotide pyrophosphatase/phosphodiesterase 3 The basophil activation marker defined by antibody 97A6 is identical to the (2013) (1)
The Role of OX40 and Its Ligand in Acute Myeloid Leukemia: Expression, Function and Modulation of NK Cell Anti-Leukemia Reactivity (2012) (1)
Daily G-CSF (filgrastim) and a Single Dose Of Pegylated G-CSF (pegfilgrastim) After Chemotherapy Result In Different Kinetics Of Circulating Hematopoetic Progenitors: Implication For Potential Stem Cell Harvesting (2013) (1)
Safety and Efficacy of Thiotepa-Based Conditioning Therapy for Allogeneic Transplantation in Acute Myeloid Leukemia - a Survey from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (2014) (1)
SIRT2 Plays Essential Role in Early Hematopoiesis through Deacetylation of LMO2 Protein (2015) (1)
Induction of NK and T Cell Immune Responses Against Leukemia Cells By Bispecific NKG2D-CD16 and -CD3 Fusion Proteins (2015) (1)
Analysis of c-sis/PDGF-B mRNA expression in megakaryocytic cells of patients with myeloproliferative disorders. (1990) (1)
Inhibition of PI3K/Akt and Erk Signaling Pathways by BCR-ABL Tyrosine Kinase Inhibitors up-Regulates the Immunosuppressive Receptor Osteoactivin in Monocyte-Derived Dendritic Cells (2012) (1)
110 High-dose therapy with etopside, ifosfamide, carboplatin, and epirubicin (VIP-E) in small cell lung cancer (SCLC) (1997) (1)
Dose Escalated Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Aggressive Non-Hodgkin Lymphoma: An Interim Analysis of a Phase I/II Study (2008) (1)
High-Dose Chemotherapy with Hematopoietic Stem Cell Transplantation for Patients with Advanced Multiple Myeloma (2000) (1)
Belimumab, a Neutralizing BAFF (B Cell Activating Factor) Antibody, Enhances the Susceptibility of Chronic Lymphoid Leukemia (CLL) Cells to Abt-199 Treatment (2015) (1)
A non-comparative phase II study of pemetrexed in patients with pretreated soft tissue sarcoma: German Sarcoma Group/AIO 005 (2008) (1)
106 High-dose therapy with etoposide, ifosfamide, carboplatin, and epirubicin (VIC-E) in non-small cell lung cancer (NSCLC) (1997) (1)
Transfer of MHC Class I by Coating Platelets Enables Tumor Cells to Evade NK Cell Immune Surveillance by Conferring a “Pseudo Self” Phenotype (2010) (1)
Basic (PS01–PS58) (2012) (1)
Clinical use for expanded peripheral blood stem cells. (1999) (1)
Genetic and Functional Characterization of Isolated Stromal Cell Lines from the Aorta-Gonado-Mesonephros (AGM)-Region. (2004) (1)
Prospective Randomized Comparison of High Dose AraC and Autologous Peripheral Blood Stem Cell Transplantation as Late Consolidation for Patients ≤60 Years with Standard Risk AML. (2005) (1)
Characterization Of The HLA Class II Ligandome In Acute Myeloid Leukemia (AML) Reveals Novel Candidates For Peptide-Based Immunotherapy (2013) (1)
Prognostic Factors in Patients Receiving An Allogeneic Stem Cell Transplantation for Relapsed AML. Results of the Prospective AML 295 and 01/99 Studies (2008) (1)
CMV infection not responding to antiviral chemotherapy specific T cells for the treatment of - Infusion of cytomegalovirus (CMV) (2013) (1)
Her-2/neu-derived Peptides Are Tumor-associated Antigens Expressed by Human Renal Cell and Colon Carcinoma Lines and Are Recognized by in Vitro Induced Specific Cytotoxic T Lymphocytes1 (2006) (1)
Zoledronic Acid Inhibits the Function of Toll-Like Receptor 4 Ligand Activated Dendritic Cells. (2006) (1)
Associated With Primary Mediastinal Nonsemino-matous Germ Cell Tumors (1999) (1)
Malignant fibrous histiocytoma of bone - Review of thirteen cases. (1996) (1)
Evaluation of residual or recurrent malignant lymphoma by FDG-PET (1997) (1)
Similarities and Differences in Signal Transduction and Crosstalk of the G Protein-Coupled Receptors CXCR4 and CysLT1 in CD34+ Hematopoietic Stem/Progenitor Cells, (2011) (1)
849 Multidisciplinary treatment of central nervous system (CNS) metastases in patients with metastatic testicular germ cell tumor (GCT) (2003) (1)
Lymphocytes Are Dispensable In Neutrophil Homeostasis. (2010) (1)
Identification of Naturally Presented HLA Ligands of Enriched Leukemic Progenitor Cells for Peptide-Based Immunotherapy in Acute Myeloid Leukemia (AML) (2016) (1)
Sphingosine 1-Phosphate (S1P) Induces Migration and ERK/MAP-Kinase-Dependent Proliferation in Chronic Lymphocytic Leukemia (B-CLL) Due to Expression of the G Protein-Coupled Receptors S1P1/4. (2005) (1)
ESTIC position paper: high-dose chemotherapy for breast cancer, investigation should continue. (1999) (1)
Expression and Immunomodulatory Function of RANKL in Leukemia (2011) (1)
Bimodal Induction of NK Cell Reactivity Against Acute Myeloid (AML) and Chronic Lymphoid Leukemia (CLL) by Fc-Engineered GITR-Fc Fusion Proteins. (2012) (1)
Allogeneic Hematopoietic Cell Transplantation with FLAMSA-RIC Can Overcome the Poor Prognosis of Primary Refractory or Relapsed AML (2011) (0)
Achievement Of a MR5.0 Within the Randomized CML-Study IV: Feasibility, Differences Between Treatment Arms, and Prognostic Implications (2013) (0)
Gonadal late effects, fertility and sexual functioning in long-term survivors after high-dose chemotherapy with autologous stem cell transplantation (HD-CT) for testicular cancer. (2004) (0)
NFAT2 Regulates Anergy Induction in CLL through Lck (2014) (0)
Identification of prognostic subgroups in patients (PTS) with poor risk germ cell cancer (GCT): a cart analysis (1999) (0)
Delayed Immune Reconstitution After Allogeneic Hematopoietic Cell Transplantation with Yttrium-90 Ibritumomab Tiuxetan-Based Reduced-Intensity Conditioning (2012) (0)
RETRACTED ARTICLE: Immuntherapie des multiplen Myeloms (2017) (0)
Multicenter Randomized Phase III Study Evaluating the Role of High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Support in Patients with Limited-Stage Small-Cell Lung Cancer (1998) (0)
A 63-Year-Old Patient with Multicentric Castleman’s Disease and Severe Polyradiculitis (1997) (0)
Inhibition of Calcineurin/NFAT Signalling Breaks Resistance of Ph+ ALL to Imatinib (2011) (0)
Toll-Like Receptor-Induced Expression of the NKG2D Ligand MICA on Monocytes Modulates Their Interaction with NK Cells. (2007) (0)
Abstract 2496: Epothilones synergistically induce CRC cell death in combination with standard chemotherapy in part through a p53-dependent pathway (2010) (0)
The patients' perspective on maintanance therapy (MT): Results of a survey applying a semistructured interview. (2011) (0)
Human GITR Ligand Is Expressed on Tumor Cells and Reduces Cytokine Production and Cellular Cytotoxicity of NK Cells Identified to Express GITR. (2005) (0)
Systemic Mastocytosis (1993) (0)
Prolonged Survival of Chronic Lymphocytic Leukemia Cells Induced by Sphingosine 1-Phosphate Is Mediated by the G Protein-Coupled Receptor S1P1 and Involves Erk/MAP Kinase, but Not Akt Signaling. (2006) (0)
iPSC Model of Stepwise Leukemia Development in Congenital Neutropenia Reveals BAALC as a Key Mediator of Leukemogenesis (2019) (0)
Rapid Reconstitution of Human Antibody Secreting Cells After Haploidentical Allogeneic Stem Cell Transplantation. (2009) (0)
A process for the preparation of a preparation of platelets and platelet preparation (1999) (0)
Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns (2016) (0)
Identification of B cells in multiline derived from cells of patients with I (pluripotent stem cells/myelolymphopoietic progenitors/human stem 4 (2016) (0)
Treatment of relapsed non-Hodgkin’s lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantation (1997) (0)
PPAR-gamma agonists inhibit toll-like receptor mediated activation of dendritic cells via MAP kinase and NF-kappaB pathways (2010) (0)
[Proliferation and differentiation in megakaryopoiesis]. (1990) (0)
Immunocytokines with Target Cell-Restricted IL-15 Activity for Induction of NK Cell Reactivity Against Acute Myeloid Leukemia (AML) (2018) (0)
Determination of Soluble MICA in Serum as a Novel Marker for Tumor Stage and Metastasis. (2004) (0)
Mechanism of BAALC-Mediated Leukemogenesis Downstream of RUNX1-Mutations in Severe Congenital Neutropenia (2018) (0)
Subject Index Vol. 20, 1997 (1997) (0)
Haploidentical Transplantation As Salvage Therapy For Disease Relapse After Allogeneic Hematopoietic Cell Transplantation (2013) (0)
Meeting summary: International Symposium and Workshop on Hematopoietic Stem Cells III, University of Tübingen, Germany, September 14-16, 2000. (2001) (0)
Phase II study of 24 hours-infusion of 5-fluorouracil and high dose folinic acid in patients with progressive or recurrent colorectal cancer (CRC) (1997) (0)
NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia (2017) (0)
Neoadjuvant chemo-radiation with paclitaxel/carboplatin in stage III non small cell lung [NSCLC] patients (2001) (0)
Congress Report – Kongreßbericht (1997) (0)
[Therapy for advanced colorectal carcinoma--new developments and standards]. (2005) (0)
Consequences of expression and release of MIC molecules by malignant cells. (2004) (0)
Case report Successful treatment of human herpesvirus-6 encephalitis after bone marrow transplantation (1999) (0)
Haploidentical Allogeneic Hematopoietic Cell Transplantation in Adults with Reduced-Intensity Conditioning and CD3/CD19-Depleted Grafts: Low Toxicity and Fast Engraftment. (2006) (0)
Hematopoietic growth factors in peripheral blood progenitor cell transplantation (1994) (0)
Long-Term Coculture of Adult Human Healthy Donor CD34+ Cells Shows Elevation of Telomeres in a Subgroup of Donors Independent of Age, Stem Cell Function and Telomerase Activity. (2004) (0)
A Method to Fluorescently Label the CRISPR/Cas9-gRNA RNP Complexes Enables Enrichment of Clinical-Grade Gene-Edited Primary Hematopoietic Stem Cells and iPSCs (2018) (0)
A reply to "A modern approach to Advanced Non-Small Cell Lung Cancer: Minimally-invasive procedures and in parallel multiple DNA/RNA high-throughput sequencing". (2020) (0)
Regulation of Dendritic Cell Function by Histone Deacetylase Inhibitors. (2006) (0)
KIT Inhibition Affects Heat Shock Protein (HSP) Activity: A Potential Rescue Mechanism towards KIT Tyrosine Kinase Inhibition and a Rationale for Dual KIT/HSP Inhibition. (2009) (0)
Central Nervous System Complications After Allogeneic Hematopoietic Cell Transplantation – Treatment Related Morbidity, Toxicity, Graft Versus Host Disease Or New Autoimmunity (2013) (0)
Impact of Donor Source and Match on Outcome of Allogeneic Hematopoietic Cell Transplantation with Reduced Intensity Conditioning (2010) (0)
HLA Ligandome Analysis in Multiple Myeloma Reveals Novel Naturally Presented Myeloma-Associated Antigens Showing Stable Expression Under Proteasome Inhibitor Therapy (2014) (0)
The management of primary mediastinal B-cell lymphoma with sclerosis (1994) (0)
Salvage Allogeneic Hematopoietic Cell Transplantation for Relapsed or Progressive Multiple Myeloma After Autologous Hematopoietic Cell Transplantation (2012) (0)
CD34 Selected Stem Cells Boosts Are Safe and Effective for Patients with Poor Bone Marrow Function After Allogeneic Hematopoietic Cell Transplantation. (2012) (0)
C-CBL Is a Critical Negative Regulator of Megakaryopoesis (2014) (0)
Abstract 658: Translational theranostic imaging of lymphoma using radiolabeled αCD19-antibodies (2018) (0)
Clinical impact and follow-up of taste disturbances following myeloablative or nonmyeloablative chemotherapy and stem cell transplantation. (2009) (0)
Clinical Outcome of Topotecan: New Strategies Play an Important Role in the Treatment of Lung Cancer, Other Solid Tumors, and Hemoblastosis (1998) (0)
14th Annual Meeting Oberrheinische Arbeitsgemeinschaft für Onkologie (OAO). Groupe de Travail des Oncologues du Rhin Supérieur (GTOR), Metz, February 6–7, 1998 (1997) (0)
Mobilization of Peripheral Blood Progenitor Cells by Hematopoietic Growth Factors for Use in High-Dose Chemotherapy (1994) (0)
CDX2 regulates Human Leukemogenesis Via Modulation Of The Wnt-Signaling Pathway (2013) (0)
[Stem cell reserve after autologous blood stem cell transplantation]. (1999) (0)
Randomized comparison of pegylated IFN-a2b versus IFN-a2b maintenance following tandem autologous transplant in multiple myeloma (2016) (0)
The Immune-Inhibitory Receptor Osteoactivin Is up-Regulated In Monocyte-Derived Dendritic Cells Upon Exposure to Tyrosine Kinase Inhibitors (2010) (0)
HLA Class I Ligandome Analysis In Acute Myeloid Leukemia – Novel T-Cell Epitopes For Peptide-Based Immunotherapy (2013) (0)
Immunosuppressive Drugs Upregulate the Immunoinhibitory Receptor Osteoactivin in Monocyte-Derived Dendritic Cells, (2011) (0)
A Fc-Engineered RANK-Fc Fusion Protein Neutralizes Soluble RANK Ligand and Targets Malignant Hematopoietic Cells for NK Cell Reactivity. (2009) (0)
BCR-ABL Tyrosine Kinase Inhibitors Interfere with the PI3K/Akt Signalling Pathway and Activate the Microphthalmia-Associated Transcription Factor (MITF) in Human Dendritic Cells (2014) (0)
Induction of Localized TNF Activity Against Tumors Using Bispecific Antibodies. (2005) (0)
Thyroid toxicity after treatment of Hodgkin's disease (1997) (0)
Mass Spectrometry-Based Immunopeptidome Analysis of Acute Myeloid Leukemia Cells Under Decitabine Treatment Delineates Induced Presentation of Cancer/Testis Antigens on HLA Class I Molecules (2018) (0)
Transcriptional Mistargeting Of NFAT2 In CLL (2013) (0)
Differential Effects of the BCR-ABL-Inhibitors Imatinib, Nilotinib and Dasatinib on NK Cell Reactivity against Chronic Myeloid Leukemia (CML) (2008) (0)
NFAT2 Is a Critical Regulator Of Anergy Induction In CLL (2013) (0)
Autocrine Function of Cysteinyl-Leukotrienes and Their Receptor CysLT1 in Chronic Lymphocytic Leukemia (B-CLL). (2009) (0)
FRI0368 Autologous stem cell transplantation with a conditioning regimen using thiotepa in patients with systemic sclerosis and cardiac manifestation (2013) (0)
Development of New Autoimmunity Against T Cell Antigens Derived From Retinal Proteins After Allogeneic Hematopoietic Cell Transplantation. (2012) (0)
Contents, Vol. 20, 1997 (1997) (0)
[Pulmonary infection in neutropenia]. (2015) (0)
A Two-Fold Rise of BCR-ABL Transcript Levels Advises BCR-ABL Mutation Analysis in Imatinib-Treated Chronic Myeloid Leukemia (CML) - an Analysis of the Randomized CML-Study IV (2014) (0)
Haematopoietic Growth Factors for the Expansion of Peripheral Blood Progenitor Cells (1997) (0)
Differential Signaling of G Protein-Coupled Chemotactic Receptors (CXCR4, cysLT1 and S1P1) Expressed in Hematopoietic Progenitor Cells. (2006) (0)
Autologous Stem Cell Transplantation (ASCT) for Enteropathy-Associated T-Cell Lymphoma (EATL) : Final Analysis of a Retrospective Study On the Behalf of Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT). (2012) (0)
Thrombopoietin (TPO) Induces Hematopoietic Differentiation of Mouse ES Cells Via HIF-1 Alpha-Dependent Activation of a BMP4 Autoregulatory Loop (2015) (0)
Amlfostine protects against acute clsplatin/ifosfamide-induced kidney damage assessed by measurement of glomerular and tubular enzymes (1997) (0)
Hematopoietic stem cells V (2015) (0)
Author ' s response to reviews Title : Expression of the embryonic stem cell marker SOX 2 in early-stage breast carcinoma (2010) (0)
[Hematologic chest pain]. (2016) (0)
hDectin-1 Is Involved in the Uptake of Apoptotic and Infected Cells and Mediates Cross-Presentation of Engulfed Antigens. (2005) (0)
Author ' s response to reviews Title : Expression of the embryonic stem cell marker SOX 2 in early-stage breast carcinoma (2010) (0)
Invariant Natural Killer T Cells from Donor Lymphocyte Infusions (DLI-iNKTs) Contribute to Anti-Tumor Immunity after Allogeneic Hematopoietic Cell Transplantation (2018) (0)
Fc-Engineered RANK-Fc Fusion Proteins for Neutralization of Soluble RANKL and Induction of Antibody-Dependent Cellular Cytotoxicity (ADCC) Against Multiple Myeloma (2010) (0)
The Ligand of Glucocorticoid-Induced TNF Receptor Is Expressed on Human Macrophages and Stimulates Proinflammatory and Anti-Tumor Effector Functions. (2006) (0)
Impaired DNA Damage Repair in Severe Congenital Neutropenia Patients (2016) (0)
Interdisciplinary management of central nervous system metastasis and neoplastic meningitis: recent developments and future perspectives (2016) (0)
Interleukin-10 Severely Impairs TLR Mediated Activation of Antigen Presenting Cells. (2006) (0)
Immune regulatory loops determ within human T lymphocyte-den4 (2016) (0)
Clinical and Radiographic Course of Bone Disease in Relapsed Multiple Myeloma in the Era of Novel Agents: Occurrence, Definition and Impact of Resclerosis Documented by Whole-Body Low-Dose Multidetector Computed Tomography (2012) (0)
Stem cell mobilization II - critical issues (1993) (0)
Absolute BCR-ABL Transcript Levels At 3 Months but Not At Diagnosis Predict Survival of Chronic Myeloid Leukemia (CML) Patients On Imatinib Therapy (2012) (0)
Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-£uorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer (2002) (0)
CRISPR/Cas9 Gene-modification Platform of ELANE Mutations in iPSCs and HSPCs of Severe Congenital Neutropenia Patients (2019) (0)
The relative risk of secondary tumors in extragonadal germ cell tumors (EGGCT) (1999) (0)
Graft versus Host Disease of the retina and recognition of self-antigens after allogeneic hematopoietic cell transplantation (2015) (0)
Abstract PR06: Molecular and functional interactions between AKT and SOX2 in breast carcinoma (2016) (0)
Reduced-Intensity Conditioning with Fludarabine and Busulfan: Age Has No Negative Impact On Survival (2012) (0)
Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial (2022) (0)
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network (2022) (0)
Ca2+/NFAT Signaling Regulates the Expression CD38 and ZAP70 in Murine B Cells and Controls B1a Cell Homeostasis (2011) (0)
Abrogated GADD45b-Mediated Integrity Control of Hematopoietic Stem Cells upon ER Stress and DNA Damage Triggers Lymphopoiesis over Granulopoiesis in Congenital Neutropenia (2017) (0)
The Role of Her2/Neu in ALL: Long Term Clinical Follow-up of Surface-Positive Patients and Induction of NK Cell ADCC by Trastuzumab in Vitro (2012) (0)
Evaluation of tumor board recommendations as the center of gastrointestinal oncology (ZGO) at Tübingen University (2003) (0)
transplantation undergoing high-dose therapy and autologous blood stem cell Long-term follow-up on a patient with incomplete POEMS syndrome (2011) (0)
Iv Vitro Modeling of the Use of FLT3 Inhibitors To Reduce Chemotherapy Doses for Elderly Patients with AML. (2007) (0)
EVI-1 Mediates Apoptosis Resistance Via CD261 Induction and Enhances Leukemogenic Potential in Human Acute Lymphoblastic Leukemia (2011) (0)
CDX2 regulates Human Leukemic Cell Clonogenicity and in Vivo Repopulation Capacity (2014) (0)
Pre-clinical and Early Clinical Experience Using Dendritic Cells to Treat Human Malignancy (1999) (0)
Tyrosine Kinase Inhibitors Only Partially Inhibit AKT-Dependent Signaling in Cells Expressing Oncogenic KIT, FLT3 or ABL Kinases. A Potential Model for Leukemia Cell Resistance to TKIs. (2007) (0)
CD34(+)- selected human peripheral blood progenitor cells Maintenance of transplantation potential in ex vivo expanded (2011) (0)
Apoptosis Stimulating Protein of p53 (ASPP2) Heterozygous Mice Are Lymphoma-Prone and Display Attenuated Apoptosis and Cell Cycle Checkpoints (2008) (0)
Long-term survival of patients with MDS after allogeneic transplantation : a report from the Chronic Malignancies Working Party of EBMT (2017) (0)
Introduction (1997) (0)
THE CLINICAL ROLE OF HEMATOPOIETIC GROWTH FACTORS IN PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION (1994) (0)
Sequential Chemotherapy Followed by Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation (allo-SCT) in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): A Survey From the Acute Leukemia Working Party of EBMT (2012) (0)
The Cytogenetic Profile In Lymphoid and Myeloid CML Blast Crisis (2013) (0)
Nicotinamidephosphoribosyltransferase (NAMPT) Induces Ubiquitination of LEF-1 Transcription Factor By Deacetylation (2015) (0)
Donor Lymphocyte Infusion Vs. Second Allogeneic HCT In Relapsed AML After Allografting: A Landmark Analysis From The Acute Leukemia Working Party Of EBMT (2013) (0)
Haploidentical TCRab Depleted Hematopoietic Cell Transplantation Leads To Rapid Immune Reconstitution and Promising Clinical Outcome In Adults (2013) (0)
International Symposium and Workshop on Hematopoietic Stem Cells VII, University of Tübingen, Germany, September 18–20, 2008 (2009) (0)
Immunological characterization of naturally presented non-mutant CML-associated HLA ligands reveals novel CD8(+) and CD4(+) T cell epitopes for immunotherapeutic approaches (2017) (0)
Efficacy and safety of imatinib in CML over 10 years. (2014) (0)
Peptide to induce an immune response against tumor cells containing them pharmzeutische compositions, uses thereof, nucleic acid coding therefor and these nucleic acid expression vector containing (1999) (0)
9 Ex vivo manipulation and clinical use of peripheral blood progenitor cells in cancer patients (1995) (0)
Prognostic V alue o f M inimal R esidual D isease Q uantification by R eal-Time R everse T ranscriptase P olymerase C hain Reaction i n P atients W ith C ore B inding F actor L eukemias (2003) (0)
The Role of Activation-Induced C-Type Lectin (AICL) in NK Cell Reactivity against Acute Leukemia (2008) (0)
Activation of C/EBPa Myeloid-Specific Transcription Factor By NAMPT/SIRT1-Triggered Deacetylation (2015) (0)
Attenuation of Apoptosis-Stimulating Protein of p53 2 (ASPP2 or TP53BP2) Associates with High Risk Disease and Therapy Failure in Acute Leukemia (2012) (0)
Abstract 2015: Novel oncogenic roles of EVI1 in breast carcinoma (2016) (0)
The G Protein-Coupled Receptor cysLT1 Signals Via ERK/MAP-Kinase and Pyk2, but Not NF-kappa B, in CD34+ Progenitor Cells, Explaining Its Dual Effect on Both, Cell Migration and Proliferation. (2005) (0)
The Role of Leukemia Derived B7-H1 in Tumor-T-Cell Interactions in Humans. (2005) (0)
GADD45b plays an essential role in the G-CSF triggered granulocytic differentiation of human hematopoietic cells (2018) (0)
The role of paclitaxel in the first-line treatment of patients with 'poor prognosis' germ cell tumor (GCT) undergoing sequential high dose chemotherapy. (2004) (0)
Deregulated integrity control of HSC pool with elevated UPR and DNA damage responses in hematopoietic cells of CN patients (2017) (0)
Loss of NFAT2 Leads to an Acceleration of Clonal Evolution in CLL (2016) (0)
Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome (MDS) Using Treosulfan Based Compared to Standard Reduced-Intensity or Myeloablative Conditioning Regimens. a Report of the Chronic Malignancies Working Party of EBMT (2020) (0)
HLA ligandome analysis of different hematological malignancies identifies a small panel of naturally presented 'pan-leukemia' antigens (2016) (0)
The value of PET/CT with 18F-FLT and 18F-FDG in the management of metastatic germ cell tumors (GCT): A pilot study. (2016) (0)
Comprar Hematopoietic Stem Cells VI | Willem E. Fibbe | 9781573316767 | Blackwell Publishing (2007) (0)
A process for the preparation of dendritic cells, cells thus obtained, and container for carrying out this method (1994) (0)
A peptide antigen MUC-1 DNA corresponding to elicit an immune response against tumor cells (2000) (0)
Pathophysiology of cytokines and therapeutic strategies in acute myeloid leukemia (1992) (0)
Imatinib Inhibits Proteasomal Activity in CML Cells. (2007) (0)
Identification of Novel Tumor-Associated Antigens for Chronic Lymphocytic Leukemia (CLL) Based On HLA Ligandome Analysis – New Targets for Peptide Based Immunotherapy (2012) (0)
[Follow-up Care in Cancer: Selected Solid Tumors and Hematological Neoplasias]. (2018) (0)
Outcome of Allogeneic Hematopoietic Cell Transplantation in AML or MDS with a HLA-Mismatched Unrelated Donor: A Single Center Analysis (2014) (0)
The G Protein-Coupled Receptor cysLT1 Mediates Gi Protein-Dependent Chemotaxis and Adhesion of CD34+ Cells in Vitro Similar to CXCR4, but Not Progenitor Mobilization in Vivo. (2008) (0)
Cryobiopsy to increase the detection rate of EGRF-mutations in non-small cell lung cancer. (2016) (0)
[Systemic mastocytosis]. (2005) (0)
The HLA Ligandome Landscape of Chronic Myeloid Leukemia Delineates Novel T-Cell Epitopes for Immunotherapy (2018) (0)
Adhesion and Proliferation of CD34 Hematopoietic Progenitor Cells (2009) (0)
HLA Ligandome Profiling Identifies a Novel Category of Pathophysiologically Relevant CLL Associated Antigens (2014) (0)
Introduction (2007) (0)
Abstract A112: Mapping the impact of proteasome inhibitor therapy on the antigenic landscape of multiple myeloma: Identifying robust targets for T cell immunotherapy (2016) (0)
CML Study IV of CML: long-term observation of 1151 patients from the randomized Impact of additional cytogenetic aberrations at diagnosis on prognosis (2012) (0)
Incipient Release of Leukocytes After Allogeneic Hematopoietic Cell Transplantation Is Indicated by Increasing Serum Levels of Uric Acid Before Detection of First Leukocytes (2010) (0)
Ex Vivo Manipulation of Peripheral Blood CD34+ Cells (1998) (0)
Analysis of Platelets in Solid Tumor Patients: Profound Changes and Unexpected Findings. (2009) (0)
Favorable Immune Signature in CLL Patients, Defined By Antigen-Specific T-Cell Responses, Might Prevent Secondary Skin Cancers (2015) (0)
Expression of the embryonic stem cell marker SOX2 in breast carcinoma (2011) (0)
Correction for Kowalewski et al., HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL) (2015) (0)
Targeting RANKL for Immunotherapy of Multiple Myeloma (2011) (0)
Methods for labeling of cells with this method, labeled cells, using the wild-type adeno-associated virus to label cells and test kits for the detection of the wild-type adeno-associated virus in cells (1993) (0)
Preface (1999) (0)
Elevated Heat Shock Protein 70 (HSP70) Serum Levels After Tumor Radiofrequency Ablation Might Represent a Favorable Prognostic Marker. (2009) (0)
QUANTITATION OF CD34+ CELLS. REPLY (1992) (0)
Serum Uric Acid Levels Can Serve As a Sensitive Biomarker for Immunologic Activity in Patients Undergoing Hematopoietic Cell Transplantation (2011) (0)
THIOTEPA-BASED CONDITIONING PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) FOR ACUTE MYELOID LEUKEMIA (AML) - A SURVEY FROM THE ALWP OF THE EBMT (2014) (0)
Role of CD137/4-1BB and Its Ligand in the NK Cell Mediated Immune Surveillance of Acute Myeloid Leukemia. (2007) (0)
The G Protein-Coupled Receptor cysLT1 Is Expressed in Acute Myeloid Leukemia Mediating Cell Migration and Survival. (2006) (0)
Cysteinyl Leukotrienes Signal Via Overexpressed CysLT1, but Not CysLT2 Receptor In Chronic Lymphocytic Leukemia (2010) (0)
Incidence and Characterization of Taste Disturbances After Allogeneic or Autologous Hematopoietic Stem Cell Transplantation Using Myeloablative or Reduced-Intensity-Conditioning. (2009) (0)
The Effects of Imatinib on the Function of Monocyte Derived Dendritic Cells Are Mediated Via the Inhibition of Akt and NF-kappaB Signal Transduction Pathways. (2004) (0)
4-1BB Ligand Mediates a “Vicious Cycle” of Immune Evasion Upon Reciprocal Interaction of Chronic Lymphocytic Leukemia and NK Cells (2010) (0)
A453 Total Marrow Irradiation, Busulfan, and Cyclophosphamide Is Equivalent to Tandem Melphalan in Myeloma (2009) (0)
The benefit of whole-body low-dose unenhanced multidetector computer tomography (WBLD-MDCT) for follow up and therapy response monitoring in patients with multiple myeloma: Correlation with hematologic parameters. (2006) (0)
' s response to reviews Title : Severe paraneoplastic hypereosinophilia in metastatic renal cell carcinoma (2012) (0)
Interplay Between the Immune System and Colorectal Carcinoma - Towards Tumor-Specific Peptide-Based Vaccination for Any HLA-Type (2015) (0)
Echinococcosis of the kidney. (1993) (0)
The Use of in Behçet's Disease - Review of the Literature and Possible Mechanisms of Action (2003) (0)
Retraction Note: Immuntherapie des multiplen Myeloms (2018) (0)
KIR Haplotype B Donors but Not KIR-Ligand Mismatch Result in a Reduced Risk of Relapse After Haploidentical Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning and a CD3/CD19 Depleted Graft. (2012) (0)
Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome; A More Favorable Outcome after Fludarabine and Treosulfan Conditioning. a Survey on Behalf of the Chronic Malignancies Working Party of the EBMT (2014) (0)
A Dual Role of Evi-1 During Developmental Hematopoiesis (2012) (0)
Annual meeting of the german society of hematology and oncology Tübingen, October 5–8, 1986 abstracts (2004) (0)
Attenuation of Apoptosis-Stimulating Protein of p53-2 (ASPP2) Promotes IL-3-Independent Growth and Enhances Cytogenetic Abnormalities after Gamma-Irradiation in Mouse Hematopoietic Cells - Mimicking Early Leukemogenesis of Therapy-Associated Human AML (2015) (0)
Pulmonale Infektion bei Neutropenie – Fall 1/2015 (2015) (0)
Subject Index, Vol. 76, 1986 (1986) (0)
Induction of NK Cell Reactivity Against AML Cells by Fc-Engineered RANK-Ig Fusion Proteins. (2012) (0)
Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias. (2006) (0)
Transplantation of Ex-Vivo Expanded Peripheral Blood Progenitor Cells After High Dose Chemotherapy in Cancer Patients (1996) (0)
Preface (2003) (0)
HLA Ligandome Analysis of Different Hematological Malignancies Identifies a Small Panel of Pan-Leukemia-Associated Antigens (2016) (0)
Abstract A45: EVI1 – a novel oncogene in breast carcinoma (2016) (0)
Whole-Body Reduced-Dose CT As Primary Staging and during Follow-up in First-Line Treatment of Transplant-Eligible Multiple Myeloma Patients: Results of the German GMMG-MM5 Trial (2014) (0)
The Role of the PI3K-AKT-mTOR Pathway in NK Cell Anti-Tumor Reactivity. (2009) (0)
Analysis of the Multiple Myeloma HLA Peptidome Identifies a Naturally Presented Bcma-Derived Peptide As an Immunogenic T-Cell Epitope for Immunotherapeutic Approaches (2018) (0)
Generation, Functional Characterization and Clinical Application of a Novel Fc-Optimized Anti-FLT3 Antibody for the Treatment of Acute Myeloid Leukemia (2010) (0)
Identification and Characterization of T Cell Epitopes Deduced from RGS5, a Novel Broadly Expressed Tumor Antigen. (2006) (0)
Down-Regulation of Glucocorticoid-Induced TNF Receptor (GITR) Ligand on Human Tumors by Proteolytic Shedding Increases Anti-Tumor Reactivity of NK Cells. (2006) (0)
Disease and Therapy Associated Complications of the Central Nervous System after Allogeneic Hematopoietic Cell Transplantation - a Significant Proportion of Patients Will Suffer from Permanent Damage (2016) (0)
Multicolor Flow Cytometry Allows Quantitative Analysis of Signal Transduction in Murine and Human Hematopoietic Stem and Progenitor Cells (2008) (0)
Tumor and Stem Cell Biology SOX 2 Expression Associates with Stem Cell State in Human Ovarian Carcinoma (2013) (0)
Activation-Induced Release of the TNF-Family Member BAFF By NK Cells Facilitates Resistance of Chronic Lymphoid Leukemia Cells to Direct and Rituximab-Induced NK Lysis (2014) (0)
Induction of NK Cell Reactivity in Breast Cancer by Fc-Engineered NKG2D-Ig Fusion Proteins (2012) (0)
Involvement of NFAT Signaling in Function and Anti-Tumor Reactivity of NK Cells (2012) (0)
A non-comparative phase II study of bendamustine hydrochloride in patients with pretreated soft tissue sarcoma (German Sarcoma Group-AIO 001). (2006) (0)
Immunotherapy With RNA Vaccination Coding For TAA In Renal Cell Carcinoma: Update On Immunological Responses and Correlation With Survival (2013) (0)
Knock-Down of the NFAT2 Long and Intermediate Isoforms Leads to CLL Acceleration (2016) (0)
Heatshockproteins-60 and 90 Are Overexpressed In Leukemia Stem Cells and Stabilize Oncogene Signaling (2012) (0)
hDectin-1 Mediates Cross-Presentation of Epitopes Via the Cytosolic Pathway. (2007) (0)
An Fc-optimized NKG2D-Ig fusion protein for induction of NK cell reactivity against breast cancer. (2013) (0)
Contents, Vol. 76, 1986 (1986) (0)
Promises and pitfalls of cannabinoids as agents with potential anticancer efficacy (2016) (0)
Mesenchymal Stem Cell Differentiation Markers Shared with Soft Tissue Sarcomas (2008) (0)
Unique Alterations in the Immunopeptidome of Colorectal Cancer Reflect Specific Transformations in Cancer-Associated Signaling Pathways and Reveal Tumor-Specific HLA-Ligand Modulations (2016) (0)
[Immune regulation of hematopoiesis]. (1987) (0)
Corrigendum to 'Human iPSC-based model of severe congenital neutropenia reveals elevated UPR and DNA damage in CD34+ cells preceding leukemic transformation' <[Experimental Hematology, Volume 71, 2019;71:51-60]>. (2022) (0)
Self-Peptide Recognition of Posterior Eye Segment Epitopes Mediated By Allogeneic T Cells in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (2014) (0)
Identification of RGS5 as a tumor-associated antigen expressed in a broad range of human malignancies and recognized by antigen specific cytotoxic T cells. (2006) (0)
Inhibition of DOT1L and PRMT5 Promotes Anti-Tumor Activity in a Human MLL Leukemia Model Induced By CRISPR/Cas9 (2018) (0)
THE VALUE OF POST-CHEMOTHERAPY SURGERY IN THE MANAGEMENT OF PATIENTS HARBOURING LIVER METATASES FROM GERM CELL TUMOURS (2006) (0)
The Potential Role of Topotecan in the Treatment of Pediatric and Adult Soft-Tissue Sarcomas (1998) (0)
843 Role of surgery in patients with liver metastases from nonseminomatous germ cell tumors (2003) (0)
NFAT2 to regulate anergy induction in CLL through Lck. (2015) (0)
The Impact Of Balanced and Unbalanced Karyotypes On Prognosis Of CML: From Chronic Phase To Blast Crisis (2013) (0)
PROSPECTIVE MULTICENTER STUDY FOR TREATMENT OF CHRONIC MYELOCYTIC-LEUKEMIA - COMPARISON OF BUSULFAN, HYDROCYUREA AND INTERFERON ALPHA (UPDATE APRIL, 1990) (1991) (0)
Preface for Hematopoietic Stem Cells VIII (2012) (0)
interferon-gamma, and erythropoietin cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, Ex vivo expansion of enriched peripheral blood CD34+ progenitor (2011) (0)
[Allogeneic hematopoetic cell transplantation in patients with solid tumors - Contra]. (2002) (0)
Downstream effect of CSF3R and RUNX1 mutations that underlie leukemic transformations in congenital neutropenia (CN) (2019) (0)
Correction (2020) (0)
The 3-month velocity of BCR-ABL decline: a tool for predicting deep molecular response in CML patients (2016) (0)
HLA Ligandome Analysis in Primary Polycythemia Vera (PV) Samples Shows No Tumor-Association of Naturally Presented JAK2 Ligands but Reveals a Vast Array of Novel PV-Associated HLA Ligands (2014) (0)
Evi-1 Regulates Myelopoiesis and Hematopoietic Stem Cell Development in Zebrafish and Human Pluripotent Stem Cells (2011) (0)
Multiple Roles for the Zebrafish Homologue of the Murine Evi1 Gene during Primitive Myelopoiesis and HSC Development (2014) (0)
IN NORMALS AND PATIENTS WITH MYELOPROLIFERATIVE DISORDERS (1988) (0)
Muc-1 peptide antigen to trigger an immune reaction against tumor cells. (2000) (0)
Aldehyde dehydrogenase activity in serous ovarian carcinoma. (2012) (0)
Hematopoietic Development From Human Induced Pluripotent Stem Cells. (2009) (0)
[Unusual cause of macrohematuria in a 29-year-old woman]. (2013) (0)
Glucocorticoid-Induced TNFR-Related Protein (GITR) Ligand Mediates Tumor Immunoediting in Chronic Lymphocytic Leukemia and Impairs Direct and Rituximab-Induced NK Cell Anti-Leukemia Reactivity. (2009) (0)
Management of extragonadal seminoma (EG-SEM) — Results of a multicenter analysis of 104 patients (PTS) (1999) (0)
Haploidentical Allogeneic Hematopoietic Cell Transplantation in Adults with CD3/CD19-Depleted Grafts after Reduced-Intensity Conditioning: A Phase I/II Study. (2007) (0)
Recombinant human hematopoietic growth factors in clinical oncology (1991) (0)
Immunosuppressive Drugs up-Regulate the Immunoinhibitory Receptor Osteoactivin On Human Monocyte-Derived Dendritic Cells (2012) (0)
Low graft invariant natural killer T-cell dose is a risk factor for cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation. (2022) (0)
Mapping the Impact of Proteasome Inhibitor Therapy on the Immunopeptidome of Multiple Myeloma: Mass Spectrometry Identifies Robust Targets for T Cell Immunotherapy (2015) (0)
Reciprocal Interaction of Monocytes and NK Cells by Activation-Induced Expression of Ligands for the Activating Immunoreceptor NKG2D. (2005) (0)
Proaerolysin Multi Color Flow-Fish Reveals Shortened Telomere Length in GPI− as Compared to GPI+ Granulocytes from Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). (2004) (0)
Results of Second or Third Allogeneic Hematopoietic Cell Transplantation As Salvage Therapy for Patients Failing Primary Transplantation (2011) (0)
Radiofrequency Ablation of Liver Metastases from Colorectal Cancer Induces a Cancer-Specific T Cell Repertoire in Humans (2018) (0)
Differential Expression of Neutrophil Granule Protein Genes in Bone Marrow Myeloid Cells at the Peak and Nadir of Neutrophil Counts in Cyclic Neutropenia (2015) (0)
B-cell depletion in patients with rheumatoid arthritis refractant to multiple TNF blockers and the interleukin 1 receptor-antagonist anakinra. Good responses in an extreme negative selection. (2007) (0)
Peroxisome proliferator activated receptor γ (PPARγ) agonists for treatment of neoplastic diseases - in vitro data and early clinical observations in chronic myelomnocytic leukemia (CMML) and in liposarcoma (2001) (0)
An Fc-Engineered CD133 Antibody for Induction of NK Cell Reactivity Against Cancer Cells (2014) (0)
Continuous 120 hours-infusion (CI) of mitomycin C (MMC) as salvage treatment in progressive or rapidly recurrent gastric cancer (GC) (1997) (0)
Evaluation of c-sis mRNA expression by human megakaryocytic cells in normals and patients with myeloproliferative disorders. (1988) (0)
Proliferation of hematopoietic progenitor cells ex vivo and to compositions of hematopoietic growth factors (1992) (0)
452: The Value of Postchemotherapy Surgery in the Management of Patients Harbouring Liver Metatases from Germ Cell Tumors (2006) (0)
Allogeneic Hematopoietic Cell Transplantation For Patients With Primary and Secondary Myelofibrosis: Report Of a Single Center Experience (2013) (0)
High-Cut Off Dialysis In Multiple Myeloma Patients With Dialysis Dependent Acute Renal Failure Shows Durable Renal Recovery: A Long-Term Follow Up Analysis (2013) (0)
NK Cell Recognition of Hepatocellular Carcinoma by Specific Induction of NKG2D Ligands Following Treatment with the Histone Deacetylase Inhibitor Sodium Valproate. (2004) (0)
FRI0408 Invariant natural killer t cells in systemic sclerosis (2018) (0)
Standards for PBSC mobilisation and collection (2005) (0)
Prospective Randomized Comparison of High Dose AraC and AutoPBSCT as Late Consolidation for Patients ≤60 Years with Standard Risk AML: Final Results of the AML SHG-Hannover 01/99 Trial. (2006) (0)
CDX2 regulates human leukemic cell clonogenicity and in vivo leukemia initiation (2015) (0)
Effect of PEG-rHu MGDF in the induction treatment of acute myeloid leukemia (1997) (0)
Paraneoplastic granulocyte colony-stimulating factor secretion in soft tissue sarcoma mimicking myeloproliferative neoplasia: a case report (2014) (0)
NAMPT/SIRT2–mediated activation of LMO2 by deacetylation is indispensable for hematopoiesis (2017) (0)
BAALC Is a Key Mediator of Leukemia Development in Congenital Neutropenia (2017) (0)
Improving Treatment Related Mortality over Time - Data from the Non-Observational Trial on Autologous Stem Cell Transplantation in Systemic Sclerosis By the EBMT Autoimmune Diseases Working Party (ADWP) (2018) (0)
Meeting summary: International Symposium and Workshop on Hematopoietic Stem Cells VI, University of Tübingen, Germany, September 14-16, 2006. (2007) (0)
Haploidentical allogeneic haematopoietic cell transplantation with Cd34 selected stem cells for the treatment of haematologic malignancies: high survival and low incidence of Gvhd (2004) (0)
Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome: Impact of Age and Conditioning (2014) (0)
Characterization of Dendritic Cell-Specific Genes p275 and p306. (2006) (0)
Acquired Hemophilia in Women Postpartum (2001) (0)
ifosfamide, and cisplatin (see comments) stimulating factor following polychemotherapy with etoposide, administration of interleukin-3 and granulocyte-macrophage colony- Mobilization of peripheral blood progenitor cells by sequential (2011) (0)
The Innate Immune System Favors Emergency Monopoiesis at the Expense of DC Differentiation to Control Bacterial Infections (2014) (0)
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia over 70 Years of Age: On Behalf of the Acute Leukemia Working Party of the EBMT (2018) (0)
Proteasome Inhibitors Affect the Function of Human Dendritic Cells and Induce Caspase-Mediated Apoptosis. (2005) (0)
Table 1: Patient characteristics. (0)
Expression of neurotrophins and their receptors in adult sarcomas. (2013) (0)
NK Cell Anti-Tumor Immune Responses Are Impaired by Sorafenib but Not by Sunitinib (2008) (0)
Defects in Primary Hemostasis and Acquired Von Willebrand Disease As Cause of Bleeding in Patients with Multiple Myeloma (2015) (0)
Expression of Glucocorticoid-Induced TNF Receptor Ligand on Acute Myeloid Leukemia Cells Mediates the Release of Immunosuppressive Cytokines and Impairs NK Cell-Mediated Immune Surveillance. (2006) (0)
Role of Glucocorticoid-Induced TNF-Related Protein (GITR) Ligand in the Interaction of Acute Myeloid Leukemia with NK Cells. (2007) (0)
The importance of combined hematologic and CT diagnosis for monitoring response in patients with multiple myeloma treated with Bortezomib based therapy (2008) (0)
Bone Marrow Derived Mesenchymal Cells Secrete Granulopoietic Cytokines upon Danger Signaling (2014) (0)
Choroidal metastases from thymic carcinoma during pregnancy: Case Report (2015) (0)
Erratum zu: RETRACTED ARTICLE: Immuntherapie des multiplen Myeloms (2018) (0)
Establishment of an in vitro model of leukemogenic transformation in congenital neutropenia (CN) using patient derived iPSCs (2017) (0)
Introduction (2005) (0)
Commensal Bacteria Are Dispensable in Neutropenia-Induced G-CSF Regulation (2011) (0)
The Role of CD137 and Its Ligand in Chronic Lymphocytic Leukemia (CLL) (2008) (0)
[68-year-old female patient with dyspnea and hypokalemic hypertension]. (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Lothar Prof Dr Kanz?

Lothar Prof Dr Kanz is affiliated with the following schools:

University of Marburg
Ludwig Maximilian University of Munich
Hannover Medical School
University of Tübingen
University of Geneva
University of Würzburg
University of Vienna
University of Bonn

Lothar Prof Dr Kanz's Academic­Influence.com Rankings

Lothar Prof Dr Kanz's Degrees

Why Is Lothar Prof Dr Kanz Influential?

Lothar Prof Dr Kanz's Published Works

Published Works

What Schools Are Affiliated With Lothar Prof Dr Kanz?

Lothar Prof Dr Kanz's AcademicInfluence.com Rankings